Treatment composition containing ester amine or salt thereof

Abstract

Disclosed is a treatment composition comprising at least one perfume raw material and an ester amine or a salt thereof obtainable by a process using a catalytic amount of at least one orthoester; and a method of treating an article or surface, wherein the method comprises treating the article or surface with such a treatment composition, optionally in the presence of water.

Description

Technical Field

[0001] The present disclosure relates to treatment compositions comprising at least one fragrance raw material and an esteramine or salt thereof; and methods of treating articles or surfaces using such compositions. The esteramines can be obtained by processes using catalysis or substoichiometric orthoesters. Background Art

[0002] Consumers prefer treatment products (e.g., fabric treatment compositions, hard surface treatment compositions, etc.) that have a distinctly pleasant odor. The consumer products industry is continually looking for ways to improve the delivery efficiency and / or performance benefits associated with the fragrance raw materials contained in such treatment compositions. The use of fragrance delivery systems (e.g., fragrance precursors) can be a useful strategy to improve delivery efficiency. Therefore, there is a continued interest in new and improved fragrance delivery systems for treatment compositions.

[0003] Furthermore, due to increasing environmental concerns, consumers desire products that are associated with a desired environmental or sustainability profile. Therefore, some important goals of the consumer products industry are to utilize more biodegradable ingredients, improve the sustainability of cleaning formulations, avoid the accumulation of non-degradable compounds in ecosystems, and reduce the CO2 emissions associated with the manufacture or use of consumer products. 2 Therefore, there is a constant need to provide consumer products that are more environmentally friendly without sacrificing performance.

[0004] In conjunction, there is also a continuing need for treatment compositions comprising perfume delivery systems that are capable of achieving good / increased perfume delivery performance and having increased environmental friendliness. There is also a continuing need for methods of treating articles or surfaces by using such treatment compositions. Summary of the invention

[0005] The present disclosure relates to a treatment composition comprising at least one perfume raw material and an esteramine of formula (I) or a salt thereof,

[0006]

[0007] where independently of each other:

[0008] t is an integer from 1 to 100;

[0009] For each repeating unit t, A 1 are independently selected from the list consisting of vinyloxy, 1,2-propenyloxy, 1,2-butenyloxy, 2,3-butenyloxy, isobutenyloxy, pentenyloxy, hexenyloxy, styryloxy, decenyloxy, dodecenyloxy, tetradecenyloxy, and hexadecyloxy, wherein for t equal to 1, A 1 The oxygen atom of the group is combined with the B group, and the next A 1The group is always connected to the previous A 1 Group bonding;

[0010] B 1 are independently selected from the group consisting of: a bond, a straight chain C 1 To C 12 Alkanediyl and branched C 1 To C 12 Alkanediyl;

[0011] R 4 , R 8 and R 12 is selected from the group consisting of: H, linear alkyl, branched alkyl, and cycloalkyl;

[0012] The prerequisite is Z 1 is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and a compound according to formula (II), wherein the compound according to formula (II) is linked to the compound according to formula (I) via a bond marked with *, with the proviso that at least one group R 4 , R 8 and / or R 12 Containing at least 7 or more carbon atoms;

[0013]

[0014] Which independently

[0015] w is an integer from 0 to 12;

[0016] R 13 and R 14 For each repeating unit w is independently selected from the group consisting of: H, linear alkyl, branched alkyl and cycloalkyl;

[0017] R 15 , R 16 , R 17 and R 18 Selected from the group consisting of H, linear alkyl, branched alkyl and cycloalkyl.

[0018] The present disclosure also relates to a treatment composition comprising at least one perfume raw material and an esteramine or a salt thereof, the esteramine or a salt thereof being obtained by a process using a catalytic amount of at least one orthoester, the process comprising the following steps: a) reacting 1) and 2) in the presence of 3) and 4) to produce an esteramine salt: 1) at least one amino acid selected from α-amino acids, β-amino acids, γ-amino acids, δ-amino acids, ε-amino acids, etc., such as alanine, glycine, leucine, isoleucine, valine, proline, phenylalanine, arginine, asparagine, aspartic acid, acid), aspartate, glutamine, glutamic acid, histidine, lysine, threonine, tryptophan, tyrosine, cysteine, methionine, serine; α-amino acids with secondary or tertiary amino groups, such as sarcosine, N,N-dimethylglycine; other amino acids, such as 6-aminocaproic acid, 4-aminobutyric acid, 3-aminopropionic acid, 12-aminododecanoic acid, 11-aminoundecanoic acid; amino acids formally derived from the hydrolysis of α-lactams (three ring atoms), β-lactams (four ring atoms), γ-lactams (five ring atoms), etc.; such lactams are preferably β-propiolactam, g-butyrolactam, δ-valerolactam, g-valerolactam, e-caprolactam, d-decanolactam, g-decanolactam, e-decanolactam; preferably alanine, valine, β-alanine, 6-aminocaproic acid; 2) at least one alcohol (A) carrying at least one hydroxyl group, selected from monohydric alcohols, diols and polyols, all of which can optionally be alkoxylated, wherein the alkoxylation of the at least one hydroxyl group takes place in a step prior to step a), wherein the alcohol is alkoxylated with at least one alkylene oxide, preferably at least 1 mol up to 200 mol, preferably 1 mol to 100 mol, more preferably up to 50 mol of alkylene oxide per hydroxyl group; 3) at least one acid (C), chosen from inorganic acids and organic acids, wherein the organic acid or inorganic acid preferably has a pKa value of -3 up to +5, more preferably -2.5 to 1.5, preferably at least one organic acid, such as sulfonic acid, more preferably alkylsulfonic acid and / or arylsulfonic acid; 4) in the presence of at least one orthoester, such as triethyl orthoformate, trimethyl orthoformate, triethyl orthoacetate, trimethyl orthoacetate, etc.; while the orthoester is used in a substoichiometric amount, preferably a catalytic amount (referring to an amino acid), and wherein the alcohol used for esterification is different from the alcohol residual in the orthoester. Optionally, there may be an additional step of neutralizing the obtained esteramine salt with at least one base to obtain the free esteramine.The treatment composition comprises less than 0.5% alcohol (A) by weight of the treatment composition as a residue of the reaction process to obtain the esteramine or its salt.

[0019] The present disclosure also relates to a method of treating an article or surface, wherein the method comprises treating the article or surface with a treatment composition as detailed herein, optionally in the presence of water. DETAILED DESCRIPTION

[0020] The present disclosure relates to treatment compositions including at least one fragrance raw material and an esteramine or a salt thereof; and methods of treating articles or surfaces by using such compositions. In some embodiments of the treatment composition, some of the at least one fragrance raw material may be linked to the esteramine or a salt thereof by a linker at certain points (e.g., when added together as a premix, when added together to a consumer product bottle, when in contact with an article or surface, in the scrubbing portion of a hard surface cleaning process, in the washing process of fabric laundry washing, in the drying process, etc.). Without wishing to be bound by theory, it is believed that when the linker is subsequently broken (e.g., via hydrolysis or reversal), the fragrance raw material is released and delivers a fragrance delivery benefit.

[0021] Such treatment compositions and related methods of use are described in more detail below. Such treatment compositions utilize esteramines and salts thereof obtained by the methods detailed herein. When compared to esteramines and salts thereof obtained by different known reaction methods (e.g., esteramines synthesized without using such orthoesters), the treatment compositions using esteramines and salts thereof obtained by the reaction methods detailed herein will have less residual fatty alcohol (i.e., alcohol (A) as defined herein). Therefore, due to having less residual fatty alcohol in the treatment composition, the treatment composition will have a better base odor. This can be confirmed by comparing GC / MS (gas chromatography / mass spectrometry) headspace analysis of treatment compositions, which differ only in the source of the esteramines and salts thereof, and the source differs due to the reaction process of the derived esteramines and salts thereof.

[0022] In addition, for stability reasons, the methods detailed herein may preferably use monoalcohols or secondary alcohols as reactants, i.e., at least one alcohol (A). The use of monoalcohols and secondary alcohols as reactants (i.e., at least one alcohol (A)) will also result in a treatment composition containing residual monoalcohols and secondary alcohols that have not been converted into esteramines and salts thereof. Esteramines obtained from monoalcohols and secondary alcohols have improved stability compared to other esteramines.

[0023] Obviously, the esteramines and salts thereof obtained by the methods detailed herein (and by known methods using stoichiometric orthoesters) can be further refined / purified to remove even more residual fatty alcohols and thus improve the base odor of the treatment compositions in which they are used. However, each refinement / purification step consumes more energy and makes the resulting consumer product less environmentally friendly. Therefore, the ability to use the esteramines and salts thereof obtained by the methods defined herein in the treatment compositions detailed herein (without the need for additional refinement steps) allows for acceptable, more environmentally friendly treatment compositions. In other words, such treatment compositions using the esteramines obtained by the methods detailed herein also have lower CO 2 emissions when compared to esteramines prepared by alternative methods. 2In addition to the above benefits, such esteramines and their salts show good biodegradation properties when used in treatment compositions, such as fabric treatment compositions.

[0024] definition :

[0025] As used herein, the articles "a" and "an" when used in a claim are understood to refer to one or more of the things protected or described by the claim. As used herein, the terms "comprising," "including," and "containing" are intended to be non-limiting. The compositions of the present disclosure may comprise, consist essentially of, or consist of the components of the present disclosure.

[0026] The term "substantially free" may be used herein. This means that the referenced material is very small, not intentionally added to the composition to form part of the composition, or preferably the referenced material is not present at analytically detectable levels. This refers to compositions in which the referenced material is present only as an impurity in one of the other materials that are intentionally added. If present, the referenced material may be present at a level of less than 1%, or less than 0.1%, or less than 0.01%, or even 0% by weight of the composition.

[0027] In particular, the term "free of water" means that the composition contains not more than 5 wt.-% water, based on the total amount of solvent, in another embodiment not more than 1 wt.-% water, based on the total amount of solvent, and in yet other embodiments the solvent contains no water at all.

[0028] Generally, as used herein, the term "capable of being obtained by..." means that the corresponding product does not necessarily have to be produced (i.e., obtained) by the corresponding method or process described in the corresponding specific context, but includes products that exhibit all the characteristics of a product produced (obtained) by the corresponding method or process, wherein the product is not actually produced (obtained) by such a method or process. However, the term "capable of being obtained by..." also includes the more restrictive term "obtained by...", i.e., a product actually produced (obtained) by the method or process described in the corresponding specific context.

[0029] When any definition requiring a compound or a substituent of a compound to consist of "at least [a certain number] of carbon atoms" is used herein, the number of carbon atoms refers to the total number of carbon atoms in the compound or substituent of the compound. For example, for a substituent disclosed as "an alkyl ether having at least 8 carbon atoms comprising an alkylene oxide", the total number of at least 8 carbon atoms needs to be the sum of the number of carbon atoms of the alkyl portion and the number of carbon atoms of the alkylene oxide portion.

[0030] All such terms not specifically defined have their ordinary meanings known in the art of organic chemistry.

[0031] The term "containing one hydroxyl group" means that there is only one group -OH. Any functional group derived from a hydroxyl group, such as an ether group, is not considered to be an -OH group.

[0032] The term "containing at least two hydroxyl groups" refers to the presence of two or more -OH groups. The term "hydroxyl group" is equivalent to the term "hydroxyl group" or "-OH group". Therefore, alcohols / compounds having only one hydroxyl group (such as methanol or ethanol) do not belong to the definition of alcohols containing at least two hydroxyl groups of compound (A) according to the present disclosure. Any functionalized groups derived from hydroxyl groups, such as ether groups, are not considered to be -OH groups.

[0033] "Sulfonate" in the present disclosure is an anion derived from a sulfonic acid, preferably an alkylsulfonic acid and / or an arylsulfonic acid, more preferably an alkylsulfonic acid, most preferably methanesulfonic acid; such acids serve to at least partially protonate the esteramine, thereby forming the sulfonate salt of the esteramine.

[0034] As used herein, the articles "a" and "an" when used in a claim or embodiment are understood to refer to one or more of the things claimed or described. As used herein, the terms "include" and "including" are intended to be non-limiting and thus include more than just the specific items mentioned after those words.

[0035] As used herein, the term "about" encompasses the exact numerical value "X" mentioned, for example, "about X%", as well as small variations of X, including deviations from negative 5% to positive 5% of X (for this calculation, X is set to 100%), preferably from negative 2% to positive 2%, more preferably from negative 1% to positive 1%, even more preferably from negative 0.5% to positive 0.5% and smaller variations. Of course, if the given value X itself is already "100%" (such as for purity, etc.), the term "about" can obviously and therefore only means its deviation less than "100".

[0036] As used herein, "treatment compositions" include consumer product compositions for treating one or more surfaces. The treatment compositions of the present disclosure can be used in baby care, beauty care, fabric care, home care, household care, feminine care and / or health care applications, and can be used to treat, for example, hard surfaces, soft surfaces, fabrics, hair and / or skin. For clarity, the term "treatment composition" is an umbrella term that includes the non-limiting examples of "fabric treatment composition," "fabric care composition," and "hard surface treatment composition."

[0037] As used herein, the phrase "fabric care composition" includes compositions and formulations designed for treating fabrics. Such compositions include, but are not limited to, laundry cleaning compositions and detergents, fabric softening compositions, fabric enhancing compositions, fabric refreshing compositions, laundry pre-washes, laundry pre-treaters, laundry additives, spray-on products, dry cleaning agents or compositions, laundry rinse additives, washing additives, post-rinse fabric treatment agents, ironing aids, unit dose formulations, delayed delivery formulations, detergents on or included in porous substrates or nonwoven sheets, and other suitable forms that are apparent to those skilled in the art according to the teachings herein. Such compositions can be used as laundry pre-treaters, laundry post-treaters, or can be added during the rinse cycle or wash cycle of a laundry operation.

[0038] Unless otherwise indicated, all component or composition levels are in terms of the active portion of that component or composition and are exclusive of impurities, for example, residual solvents or by-products, that may be present in commercially available sources of such component or composition.

[0039] Unless otherwise indicated, all temperatures herein are in degrees Celsius (° C.) Unless otherwise indicated, all measurements herein are made at 20° C. and atmospheric pressure.

[0040] In all embodiments of the present disclosure, unless otherwise specifically stated, all percentages are by weight of the total composition. Unless otherwise specifically stated, all ratios are by weight.

[0041] It should be understood that each maximum numerical limitation given throughout this specification includes each lower numerical limitation, as if such lower numerical limitations were expressly written herein. Each minimum numerical limitation given throughout this specification will include each higher numerical limitation, as if such higher numerical limitations were expressly written herein. Each numerical range given throughout this specification will include each narrower numerical range falling within such wider numerical range, as if such narrower numerical ranges were all expressly written herein.

[0042] Structure of esteramines and their salts :

[0043] The treatment compositions detailed herein relate to alkoxylated esteramines of formula (I) and their salts,

[0044]

[0045] where independently of each other:

[0046] t is an integer from 1 to 100;

[0047] For each repeating unit t, A 1are independently selected from the list consisting of vinyloxy, 1,2-propenyloxy, 1,2-butenyloxy, 2,3-butenyloxy, isobutenyloxy, pentenyloxy, hexenyloxy, styryloxy, decenyloxy, dodecenyloxy, tetradecenyloxy, and hexadecyloxy, wherein for t equal to 1, A 1 The oxygen atom of the group is combined with the B group, and the next A 1 The group is always connected to the previous A 1 Group bonding.

[0048] B 1 Independently selected from the group consisting of: a bond, a straight chain C 1 To C 12 Alkanediyl and branched C 1 To C 12 Alkanediyl;

[0049] R 4 , R 8 and R 12 is selected from the group consisting of: H, linear alkyl, branched alkyl, and cycloalkyl;

[0050] The prerequisite is Z 1 is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and a compound according to formula (II), wherein the compound according to formula (II) is linked to the compound according to formula (I) via a bond marked with *, with the proviso that at least one group R 4 , R 8 and / or R 12 Containing at least 7 or more carbon atoms;

[0051]

[0052] Which independently

[0053] w is an integer from 0 to 12;

[0054] R 13 and R 14 For each repeating unit w is independently selected from the group consisting of: H, linear alkyl, branched alkyl and cycloalkyl;

[0055] R 15 , R 16 , R 17 and R 18 Selected from the group consisting of H, linear alkyl, branched alkyl and cycloalkyl.

[0056] The esteramines and salts thereof according to the present disclosure can be used in treatment compositions, in particular liquid fabric enhancers. In some embodiments of the treatment composition, some of the at least one fragrance raw material can be linked to the esteramine or its salt via a linker. Without wishing to be bound by theory, it is believed that when the linker is subsequently broken (e.g., via hydrolysis or reversal), the fragrance raw material is released and delivers a fragrance delivery benefit. Thus, the esteramines and salts thereof as described herein can be used as part of a pro-fragrance technology.

[0057] In the following, various embodiments of the present disclosure are described in more detail:

[0058] For each repeating unit t, A1 is independently selected from the list consisting of vinyloxy, 1,2-propenyloxy, 1,2-butenyloxy, 2,3-butenyloxy, isobutenyloxy, pentenyloxy, hexyloxy, styryloxy, decenyloxy, dodecenyloxy, tetradecenyloxy and hexadecyloxy, wherein for t equal to 1, the oxygen atom of the A1 group is bonded to the B group and the next A1 group is always bonded to the previous A1 group via the oxygen atom. When t is equal to or greater than 2, the independently selected A1 1 Either randomly distributed side chains of various alkyleneoxy units are formed, or a block structure having at least one alkyleneoxy group repeating itself at least twice is formed, optionally followed by other blocks of different alkyleneoxy groups repeating themselves at least twice.

[0059] In one embodiment, for each repeating unit t, A 1 is independently selected from the list consisting of ethyleneoxy, 1,2-propyleneoxy, 1,2-1,2-propyleneoxy and 1,2-butenyloxy. 1 A block of at least two ethyleneoxy groups is formed, followed by a block of at least two propyleneoxy groups, optionally followed by another block of at least two ethyleneoxy groups. 1 A block of at least two 1,2-propyloxy groups is formed, followed by a block of at least two ethyloxy groups, optionally followed by another block of at least two 1,2-propyleneoxy groups. 1 is selected from the list consisting of ethyleneoxy, 1,2-propyleneoxy and 1,2-butenoxy, in such a way that at least one block of ethyleneoxy, 1,2-propyleneoxy or 1,2-butenoxy is formed, optionally followed by one or more blocks of ethyleneoxy, 1,2-propyleneoxy or 1,2-butenoxy. 1 In another embodiment, A 1 In another embodiment, A 1are selected in such a way that a block of one to five ethyleneoxy groups is followed by a block of one to three propyleneoxy groups, followed by a block of one to five ethyleneoxy groups.

[0060] In one embodiment, t is in the range of 1 to 30. In another embodiment, t is in the range of 1 to 20. In another embodiment, t is in the range of 2 to 10.

[0061] In one embodiment of the present disclosure, B 1 Selected from the group consisting of: bond and straight chain C 1 To C 12 In another embodiment, B 1 Selected from the group consisting of: bond and straight chain C 1 To C 6 In another embodiment, B 1 Selected from the group consisting of: bond and straight chain C 1 To C 3 In another embodiment, B 1 Selected from the group consisting of: key and C 1 In another embodiment B 1 Selected from the group consisting of: key and C 1 In another embodiment, B 1 is the key.

[0062] In one embodiment of the present disclosure, R 4 , R 8 and R 12 are independently selected from the group consisting of: H, linear alkyl, branched alkyl, and cycloalkyl. 4 , R 8 and R 12 are independently selected from the group consisting of: H, straight chain C 1 To C 12 Alkyl and C 1 To C 12 In another embodiment, R 4 , R 8 , and R 12 are independently selected from the group consisting of: H, straight chain C 1 To C 6 Alkyl and C 1 To C 9 Branched chain alkyl.

[0063] For Z 1 is selected from compounds according to formula (II), said compound according to formula (II) being linked to a compound according to formula (I) via a bond marked with *,

[0064]

[0065] Which independently

[0066] w is an integer from 0 to 12;

[0067] R 13 and R 14 For each repeating unit w is independently selected from the group consisting of: H, linear alkyl, branched alkyl and cycloalkyl;

[0068] R 15 , R 16 , R 17 and R 18 is selected from the group consisting of: H, straight chain alkyl, branched chain alkyl and cycloalkyl. 13 , R 14 , R 15 , R 16 , R 17 and R 18 are independently selected from H, straight chain C 1 To C 12 Alkyl and C 1 To C 12 In another embodiment, R 13 , R 14 , R 15 , R 16 , R 17 and R 18 are independently selected from H, straight chain C 1 To C 6 Alkyl and C 1 To C 9 Branched chain alkyl.

[0069] In one embodiment of the present disclosure, Z 1 is selected from the group consisting of alanine, glycine, lysine and a compound according to formula (II), wherein w is an integer ranging from 1 to 4 and the compound according to formula (II) is linked to the compound according to formula (I) via a bond marked with *, with the proviso that at least one group R 4 , R 8 and / or R 12 Contains at least 7 or more carbon atoms. In another embodiment, Z 1 In another embodiment, Z 1 is a compound according to formula (II) wherein w=0 and R 15 To R 18 In another embodiment, Z 1is a compound according to formula (II) wherein w=1 and R 13 To R 18 In another embodiment, Z 1 is a compound according to formula (II) wherein w=3 and R 13 To R 18 All are H.

[0070] In another embodiment of the present disclosure, B 1 Selected from branched or straight chain C 1 - to C 12 -alkyl, and R 8 Selected from straight or branched chain C 6 - to C 23 In another embodiment of the present invention, B 1 Selected from branched or straight chain C 1 - to C 12 -alkyl, and R 8 Selected from straight or branched chain C 1 - to C 3 -alkyl. Another embodiment consists of B 1 is 2-ethylethylenediyl and R 8 It is a straight chain C 3 -alkyl composition.

[0071] In another embodiment of the present disclosure, B 1 Selected from branched or straight chain C 1 - to C 12 -alkyl, and R 8 Selected from straight or branched chain C 1 - to C 3 -alkyl, and Z 1 is a compound according to formula (II) wherein w=3, and R 13 To R 18 All are H.

[0072] In another embodiment of the present disclosure, B 1 Selected from branched or straight chain C 6 - to C 12 -alkyl, and R 8 Selected from linear or branched C 1 - to C 3 -alkyl, t is in the range of 1 to 10, for each repeating unit t, A 1 is ethyleneoxy, and Z 1 is selected from the group consisting of: alanine, a compound according to formula (II) wherein w=0 and R 15 To R 18 are all H, a compound according to formula (II), wherein w=1 and R13 To R 18 are all H and a compound according to formula (II) wherein w=3 and R 13 To R 18 Both are H.

[0073] In another embodiment of the present disclosure, B 1 Selected from branched or straight chain C 6 - to C 12 -alkyl, and R 8 Selected from linear or branched C 1 - to C 3 -alkyl, R 4 and R 12 Selected from H and straight or branched C 1 - to C 3 -alkyl, t is in the range of 1 to 10, for each repeating unit t, A 1 is 1,2-propyleneoxy, and Z 1 is selected from the group consisting of: alanine, a compound according to formula (II) wherein w=0 and R 15 To R 18 are all H, a compound according to formula (II), wherein w=1 and R 13 To R 18 are H and a compound according to formula (II) wherein w=3 and R 13 To R 18 Both are H.

[0074] The esteramines according to the present disclosure are obtained either as free amines, as salts thereof or as mixtures of free amines and salts. The salts are formed by at least partially protonating the amine groups with an acid (a protic organic acid or a protic inorganic acid). In one embodiment, the acid for at least partially protonating the amine groups is selected from the group consisting of methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, citric acid and lactic acid. In one embodiment, the acid is selected from the group consisting of methanesulfonic acid, hydrochloric acid and sulfuric acid. In another embodiment, the acid is methanesulfonic acid.

[0075] Partial protonation is protonation of the amine groups in the range of 1 mol % to 99 mol % of all amine groups in one embodiment, 10 mol % to 90 mol % of all amine groups in another embodiment, 25 mol % to 85 mol % of all amine groups in another embodiment, and 40 mol % to 75 mol % of all amine groups in another embodiment.

[0076] Method for producing esteramines and their salts :

[0077] It has surprisingly been found that the esterification of amino acids can be improved by using substoichiometric or even catalytic amounts of orthoesters. In addition and unexpectedly, esteramines can be produced in which the ester is derived from an alcohol present in a different orthoester than that used as a catalyst. Thus, the present disclosure relates to improved methods for producing esteramines and salts thereof using substoichiometric or even catalytic amounts of orthoesters.

[0078] Thus, the present disclosure relates to a treatment composition comprising an esteramine or a salt thereof produced by using a catalytic amount of at least one orthoester, the method comprising the steps of:

[0079] a) in the presence of iii) and iv), i) and ii) react to produce an esteramine salt:

[0080] i) at least one amino acid selected from α-amino acids, β-amino acids, γ-amino acids, δ-amino acids, ε-amino acids, etc., such as alanine, glycine, leucine, isoleucine, valine, proline, phenylalanine, arginine, asparagine, aspartic acid, aspartate, glutamine, glutamic acid, histidine, lysine, threonine, tryptophan, tyrosine, cysteine, methionine, serine; α-amino acids having secondary or tertiary amino groups, such as sarcosine, N,N-dimethylglycine; other amino acids, such as Such as 6-aminocaproic acid, 4-aminobutyric acid, 3-aminopropionic acid, 12-aminododecanoic acid, 11-aminoundecanoic acid; amino acids formally derived from the hydrolysis of α-lactams (three ring atoms), β-lactams (four ring atoms), γ-lactams (five ring atoms), etc.; such lactams are preferably β-propiolactam, g-butyrolactam, δ-valerolactam, g-valerolactam, e-caprolactam, d-decanolactam, g-decanolactam, e-decanolactam; preferably alanine, valine, β-alanine, 6-

[0081] Aminocaproic acid;

[0082] ii) at least one alcohol carrying at least one hydroxyl group, chosen from mono-, di- and polyols, all of which can optionally be alkoxylated, wherein the alkoxylation of at least one hydroxyl group takes place in a step preceding step a), wherein the alcohol is alkoxylated with at least one alkylene oxide, preferably at least 1 mol up to 200 mol, preferably 1 mol to 100 mol, more preferably up to 50 mol of alkylene oxide per hydroxyl group;

[0083] iii) at least one acid (C) selected from inorganic and organic acids, wherein the organic or inorganic acid preferably has a pKa value of -3 up to +5, more preferably -2.5 to 1.5, preferably at least one organic acid such as sulfonic acid, more preferably alkylsulfonic acid and / or arylsulfonic acid, more preferably alkylsulfonic acid, most preferably methanesulfonic acid;

[0084] iv) in the presence of at least one orthoester, such as triethyl orthoformate, trimethyl orthoformate, triethyl orthoacetate, trimethyl orthoacetate, and the like;

[0085] wherein the orthoester is used in a substoichiometric amount, preferably a catalytic amount (referring to the amount of the amino acid), and

[0086] wherein the alcohol used for esterification is different from the alcohol remaining in the orthoester;

[0087] b) optionally removing water and / or excess alcohol during and / or after the reaction to obtain a purified esteramine salt;

[0088] c) optionally neutralizing the obtained esteramine salt with at least one base to obtain the free esteramine.

[0089] In addition, the following method steps may optionally be included in the methods disclosed herein:

[0090] The reaction mixture can be inerted before and / or during the reaction, preferably before adding acid C. Inerting can be achieved by gaseous vapors such as nitrogen or argon and / or by adding deoxidizing compounds. Such deoxidizers are known. Advantageously, a small amount of inorganic salts having reducing properties to oxygen are used, such as hypophosphorous acid compounds, any salt such as hypophosphorous acid or their salts, especially any alkali metal or ammonium salt or alkaline earth metal salt, more preferably acid, which can be added to the reaction mixture before adding sulfuric acid. As one of the effects, when compared with omitting such interpolation, this interpolation of deoxidizing compounds causes the color of the resulting products to improve, i.e. means reducing coloring.

[0091] The reaction was carried out under the following conditions:

[0092] - at a temperature of 50°C to 200°C, preferably 70°C to 180°C, more preferably 80°C to 160°C, most preferably 120°C to 150°C, such as 60°C, 65°C, 75°C, 85°C, 90°C, 95°C, 100°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, 155°C, 165°C, 170°C, 190°C;

[0096] - for a period of 1 hour to 30 hours, preferably 2 hours, more preferably 3 hours, even more preferably at least 5 hours, and preferably up to 48 hours, more preferably up to 20 hours, even more preferably up to 15 hours, such as preferably 3 hours to 24 hours, more preferably 5 hours to 24 hours, most preferably 10 hours to 24 hours;

[0097] and

[0098] - at a pressure of 0.001 bar to 10 bar, such as 0.001 bar, more preferably 0.005 bar,

[0099] Even more preferably 0.1 bar, and preferably up to 8 bar, more preferably up to 5 bar, even more preferably up to 4 bar, such as 1 bar to 10 bar, more preferably 1 bar to 5 bar, even more preferably 1 bar to 4 bar, or such as 1 mbar to 1000 mbar, more preferably 100 mbar to 500 mbar.

[0100] Preferably, temperature, duration and pressure are as defined above individually, preferably preferred ranges of all three parameters are selected, more preferably more preferred ranges of all three parameters are selected, etc. In one embodiment, the temperature is kept constant during the reaction. In another embodiment, the temperature is varied within a temperature range during the reaction duration.

[0101] In one embodiment disclosed herein, the reaction with acid C is carried out at atmospheric pressure. In another embodiment, the reaction with acid C is carried out in a closed container at a pressure of 0.001 bar to 1 bar. In another embodiment, the reaction with acid C is carried out in a closed container at a pressure of greater than 1 bar to 10 bar.

[0102] In one embodiment, the reaction is carried out using a protective atmosphere of an inert gas such as nitrogen or argon.

[0103] In another embodiment, the inertization is carried out by adding a scavenger, preferably a small amount of an inorganic salt with reducing properties for oxygen, such as a hypophosphorous acid compound, such as hypophosphorous acid or any of their salts, especially any alkali metal or ammonium salt or alkaline earth metal salt, more preferably an acid, a hypophosphorous acid compound, more preferably hypophosphorous acid. In another embodiment, the inertization is carried out by adding a scavenger as defined above and using a protective atmosphere of an inert gas as defined above.

[0104] It is clear that temperature, pressure and duration can be selected independently of the disclosed values ​​and ranges and can be combined with each other. Similarly, the way in which inertization is achieved can also be selected and combined with the selected temperature, duration and pressure, all of which are as defined above.

[0105] During or after the reaction, preferably at least during the reaction, water and / or excess alcohol may be removed. The removal of water and alcohol may be carried out by all techniques known in the art, for example by applying a gas stream and / or by applying a distillation method, preferably a distillation method, more preferably a distillation method under reduced pressure and / or at elevated temperature, preferably both, a preferred method being the use of a device such as a Dean-Stark trap.

[0106] In another embodiment, water and / or alcohol are removed using a gas stream, such as using a gas, such as an inert gas, such as nitrogen or argon, preferably nitrogen, or steam made from water, preferably using an inert gas, more preferably nitrogen. In a more preferred embodiment, water and / or alcohol are removed by applying a vacuum and / or increasing the temperature, most preferably using a device such as a Dean-Stark trap. The optional removal of water and / or excess alcohol is more preferably carried out by applying a vacuum in the range of 0.1 mbar to 800 mbar, preferably 1 mbar to 500 mbar, more preferably 10 mbar to 100 mbar and using an elevated temperature.

[0107] In a preferred embodiment, during the reaction, an inert gas, such as nitrogen or argon, preferably a vapor of nitrogen, is passed through the reaction mixture. This helps to keep the reaction mixture inert, but also helps to remove the water formed from the chemical reaction and thus control the amount of water present.

[0108] The molar ratio of amino acid to hydroxyl group of the (optionally alkoxylated) alcohol is:

[0109] (0.8*n):1 to (1*n):1.5, wherein the number of hydroxyl groups of the (optionally alkoxylated) alcohol is n.

[0110] In one embodiment, the process is carried out in a molar ratio of acid C to amino acid in the range of 0.8:1 to 1.2:1.

[0111] Suitable solvents for the reaction may be toluene, xylene, heptanol, cyclohexene, etc., and preferably the reaction is carried out in the absence of a solvent.

[0112] In preferred embodiments, the reaction is conducted in the presence of the minimum practical amount of water, preferably is substantially free of water, and most preferably is free of water at the beginning of the reaction and for a substantial portion of the time, more preferably from the beginning of the reaction until the reaction is substantially complete.

[0113] Obviously, such amino acids are known and can usually be prepared from natural sources. Others can be produced from natural sources by modifying them to obtain amino acids as starting materials. If such modification does result in the addition of carbon atoms, for example by chemical addition reactions, and if such addition reactions use non-fossil carbon atoms, the amino acids contain only non-fossil carbon. Therefore, it is preferred to use only naturally occurring amino acids and / or naturally derived amino acids (not prepared by adding non-fossil carbon in building blocks to obtain such naturally derived amino acids) in the methods disclosed herein. Even more preferably, only naturally occurring amino acids are used.

[0114] The same applies to lactams: when lactams are obtainable from natural sources, such natural or naturally derived lactams are preferred; of course, more preferred are naturally occurring lactams in order to increase the overall non-fossil based carbon content.

[0115] at least one alcohol carrying at least one hydroxyl group, chosen from mono-, di- and polyols, all of which can optionally be alkoxylated, wherein the alkoxylation of at least one hydroxyl group takes place in a step prior to step a), wherein the alcohol is alkoxylated with at least one alkylene oxide, preferably at least 1 up to 200 mol, preferably 1 to 100 mol, more preferably up to 50 mol of alkylene oxide per hydroxyl group, and in one embodiment even more preferably up to 20 mol, such as up to 15 mol or even up to 10 mol of alkylene oxide per hydroxyl group.

[0116] Alcohols containing one hydroxyl group are well known in the art. Similarly, alcohols containing at least two hydroxyl groups according to compound (A) are known to those skilled in the art. As mentioned above, the corresponding alcohols may contain one, two, three, four, five or even more hydroxyl groups in the corresponding molecules / compounds. The corresponding alcohols may contain straight-chain, branched and / or cyclic alkyl fragments. In addition, the corresponding alcohols may also contain aromatic fragments and combinations of alkyl and aromatic fragments ("aralkyl" fragments). In addition, the corresponding alcohols may also contain alkyl ether fragments. Examples of alcohols according to compound (A) are glycerol, pentaerythritol, sorbitol, 1,1,1-trimethylolpropane (TMP), erythritol or alkoxylated alcohols, such as polyethylene glycol.

[0117] Many alcohols of compound (A) according to the present disclosure are commercially available, for example, from BASF SE under the trade name "Pluronic" or "Pluriol" (eg as polyethylene glycol block (co)polymers).

[0118] The alcohol (A) used for the inventive esteramines and the inventive process as described herein is selected from:

[0119] (a) a monohydric alcohol, such as a C1 to C36 alkanol, selected from the group consisting of: a non-alkoxylated straight-chain C2 to C36 alcohol, such as a mixture of such alcohols selected from C6 to C22 fatty alcohols, preferably C8 to C22 fatty alcohols, more preferably C12 and C14 fatty alcohols, most preferably C16 and C18 fatty alcohols; a non-alkoxylated branched C3 to C36 alcohol, such as 2-ethylhexanol, 2-propylheptanol, isotridecanol, isononanol, C9-C17 oxo alcohols;

[0120] Alkoxylated linear C2 to C36 alcohols, such as alkoxylated mixtures of C6 to C22 fatty alcohols, preferably alkoxylated mixtures of C8 to C22 fatty alcohols, more preferably alkoxylated mixtures of C12 and C14 fatty alcohols, most preferably alkoxylated mixtures of C16 and C18 fatty alcohols;

[0121] Alkoxylated branched C3 to C36 alcohols, such as alkoxylated 2-ethylhexanol, alkoxylated 2-propylheptanol, alkoxylated isotridecanol, alkoxylated isononanol, alkoxylated C9-C17 oxo alcohols;

[0122] (b) diols, such as alkyl diols, polyalkoxylated C2-C6-alkanediols carrying at least two hydroxyl groups,

[0123] (c) oligomeric alcohols, such as sugar alcohols, polyalkoxylated sugar alcohols, C3-C6-alkanetriols, polyalkoxylated C3-C6-alkanetriols carrying at least three hydroxyl groups,

[0124] (d) polyols, such as C5-C6-alkanepolyols, polyalkoxylated C5-C6-alkanepolyols, polyetherols, such as polyglycerols or dipentaerythritol or tripentaerythritol, alkoxylated polyetherols, such as alkoxylated polyglycerols, alkoxylated dipentaerythritol or tripentaerythritol,

[0125] (e) phenoxyalkanols, such as phenoxyethanol;

[0126] Therein the alcohol is preferably selected from the group consisting of monohydric alcohols and alkoxylated diols, oligomeric alcohols and alkoxylated polyols, and the alcohol is even more preferably selected from the group consisting of monohydric alcohols and alkoxylated diols.

[0127] In one embodiment of the present disclosure, at least one linear or branched C 2 - to C 36 In a preferred embodiment, at least one C 8 - to C 22 In a more preferred embodiment, C 16 - and C 18 In another more preferred embodiment, C 18 - and C 22 In another more preferred embodiment, at least one branched C 9 - to C 17 In another more preferred embodiment, a linear or branched C 8 - to C 10-monohydric alcohol. In another even more preferred embodiment thereof, 2-propylheptanol or 2-ethylhexanol is used. In another even more preferred embodiment thereof, 2-ethylhexanol is used. In another preferred embodiment of the present disclosure, at least one phenoxyalkanol is used. In another more preferred embodiment, phenoxyethanol is used.

[0128] Obviously, such alcohols are known, many of which are from natural sources. Others can be produced from natural sources by modifying them. If such modification does result in the addition of carbon atoms, for example by chemical addition reactions, and if such addition reactions use non-fossil carbon atoms, the alcohol contains only non-fossil carbon. Therefore, it is preferred to use only naturally occurring alcohols and / or naturally derived alcohols (not such naturally derived alcohols obtained by adding non-fossil carbon to the structural units) in the methods detailed herein. Even more preferably, only naturally occurring alcohols are used.

[0129] In a more preferred embodiment, the alcohol (A) used for the esteramine and the process of the invention is an alkoxylated alcohol. Such alkoxylated alcohols are typically and therefore preferably obtained by alkoxylating at least one hydroxyl group of an alcohol as defined herein with one or more alkylene oxides to produce an alkyleneoxy chain comprising one or more moieties derived from an alkylene oxide selected from C2-C22 alkylene oxides, preferably C2-C4 alkylene oxides, while the moieties derived from the alkylene oxide can be arranged in random, block or multiblock order or a combination thereof, preferably as blocks.

[0130] In one embodiment of the present disclosure, an alkyl alcohol alkoxylated with only a single alkylene oxide is used. In other embodiments, an alkyl alcohol alkoxylated with a first alkylene oxide and subsequently alkoxylated with a second alkylene oxide is used, thereby forming a block structure of different alkylene oxide blocks.

[0131] Within the context of the details herein, it is also preferred that in case compound (A) comprises an alkoxylated alcohol, the alkoxylated alcohol comprises an alkoxylated fragment based on at least one C2-C22 alkylene oxide, preferably C2-C4 alkylene oxide, more preferably ethylene oxide and / or propylene oxide, most preferably the corresponding alcohol comprises at least one block based on ethylene oxide and / or propylene oxide, and even more preferably contains only one block consisting of ethylene oxide or one block consisting of two blocks, wherein the first block - preferably the "inner block" directly connected to the hydroxyl groups of the alcohol - consists of ethylene oxide, and the second block - preferably the "outer block" connected to the ethylene oxide - consists of propylene oxide. More preferably, the EO block comprises 3 to 10 EO-derived moieties and the PO block comprises 1 to 10 PO-derived moieties. Most preferably, only ethylene oxide is used.

[0132] The alkoxylation of the alcohol can be achieved by carrying out the alkoxylation reaction with only one alkylene oxide or with more than one alkylene oxide. If more than one alkylene oxide is used, the resulting alkyl ether alcohol comprises randomly distributed alkylene oxide units, or a block of one alkylene oxide is followed by a block of another alkylene oxide, or a block of one alkylene oxide is followed by another block comprising two or more alkylene oxides arranged in a random order, or a block comprising two or more alkylene oxides is followed by another block comprising two or more alkylene oxides, wherein each such block differs in their relative amount of alkylene oxides, their arrangement of alkylene oxides and / or the identity of the alkylene oxides, so that two blocks connected to each other differ in their chemical composition and / or arrangement; any combination of such arrangements is in principle possible and is therefore encompassed by the present disclosure.

[0133] In one embodiment disclosed herein, an alkyl alcohol alkoxylated with only a single alkylene oxide is used. In other embodiments, an alkyl alcohol alkoxylated with a first alkylene oxide and subsequently alkoxylated with a second alkylene oxide is used, thereby forming a block structure of different alkylene oxide blocks.

[0134] It is clear that when switching from one block to the next, depending on how the alkoxylation reaction is carried out, there may be relatively small "regions" between the blocks, without sharp "borders" between the blocks, which borders are the same on every molecule of the alkoxylated monol, so that there may be some "dirty" structure, meaning that some very small amounts (such as one or possibly two or three) of the first alkylene oxide used may be inserted only after one or more of the second alkylene oxides have reacted; this depends largely on the conversion rate achieved by the first alkylation reaction at the point in time when the second alkylene oxide is added, that is, if there is still some unreacted amount of the first alkylene oxide at the point in time when the second alkylene oxide is added.

[0135] Similarly, it is clear that due to the statistical reaction of the alkoxylation polymerization, the block length may vary slightly from one monomer compound to the next, and thus an "alkoxylated monol" is actually a mixture of compounds with slightly different chain and block lengths.

[0136] The alkoxylation reaction can generally be carried out in the presence of a catalyst at a reaction temperature of about 70° C. to about 200° C., in another embodiment about 80° C. to about 160° C. The reaction can be carried out at a pressure of up to about 10 bar, in another embodiment, at a pressure of up to about 8 bar.

[0137] Examples of suitable catalysts include basic catalysts such as alkali metal and alkaline earth metal hydroxides (such as sodium hydroxide, potassium hydroxide and calcium hydroxide), alkali metal alkoxides (especially C 1 -C 4-sodium and potassium alcoholates such as sodium methoxide, sodium ethoxide and potassium tert-butoxide), alkali metal and alkaline earth metal hydrides such as sodium hydride and calcium hydride, and alkali metal carbonates such as sodium carbonate and potassium carbonate. In one embodiment, alkali metal hydroxides are used. In another embodiment, potassium hydroxide and sodium hydroxide are used. 2 - to C 22 Alkylene oxide, preferably C 2 -C 4 - the total amount of alkylene oxide, the base is typically used in an amount of 0.01 to 10% by weight, or 0.05 to 2% by weight.

[0138] Note that the alkylene oxide used to prepare the alkoxylated alcohols may be derived from fossil or non-fossil carbon sources or even mixtures thereof. Preferably, the amount of non-fossil carbon atoms in the alkylene oxide used is at least 10%, at least 20%, at least 40%, at least 70%, at least 95% and most preferably up to 100%, based on the non-fossil derived carbon atoms; the same applies to the total inventive compound itself. The skilled person is familiar with commercial alkylene oxide products made from non-fossil carbon sources (these products are often sold as "sustainable", "renewable" or "bio-based"). For example, Croda International, Snaith, UK sells bioethanol-based ethylene oxide and related products under the "ECO" series. Additionally, methods for preparing bio-based propylene oxide are also known (see Abraham, DS, "Production of propylene oxide from propylene glycol" Master's Thesis University of Missouri-Columbia (2007) (page 75).

[0139] The acid (C) used for the esteramines and salts thereof and the process of the invention is selected from the group consisting of:

[0140] i) sulfonic acids, such as alkylsulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, camphorsulfonic acid; alkylarylsulfonic acids, and in particular alkylbenzenesulfonic acids, such as toluenesulfonic acid (including mixtures of isomers thereof), p-toluenesulfonic acid, o-toluenesulfonic acid, m-toluenesulfonic acid, xylenesulfonic acid (mixtures of isomers), 2,6-dimethylbenzenesulfonic acid, 2,5-dimethylbenzenesulfonic acid, 2,4-dimethylbenzenesulfonic acid, 4-dodecylbenzenesulfonic acid, isopropylbenzenesulfonic acid, ethylbenzenesulfonic acid and naphthalenesulfonic acid; and

[0141] ii) Inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid.

[0142] The acid used is preferably concentrated, so that the amount of water introduced into the reaction is minimized or used as a solid. Therefore, gases such as hydrogen chloride can also be used, because this can be introduced as a gas. In one embodiment of the esteramine of the invention and the process of the invention, the acid is preferably selected from group i), more preferably p-toluenesulfonic acid and / or methanesulfonic acid, most preferably methanesulfonic acid.

[0143] In the case of amounts of water introduced into the reaction via the acid, the water may be removed using known methods such as distillation procedures and equipment such as a Dean-Stark trap and the like prior to introduction of the orthoester.

[0144] The esteramines are obtained as at least partially protonated salts in cationic form.

[0145] In a preferred embodiment, methanesulfonic acid is used as concentrated methanesulfonic acid. In another preferred embodiment, the amount of methanesulfonic acid is about 70 wt.-% methanesulfonic acid in water or "pure" acid, such as typically close to 100 wt.% purity (equal to "about 100 wt.%"); however, any concentration in between may also be used. In another preferred embodiment, the amount of methanesulfonic acid is about 70 wt.-% methanesulfonic acid-water solution. However, in a most preferred embodiment, the sulfonic acid, such as methanesulfonic acid, is introduced as a solid, even more preferably as a dry solid (to reduce the amount of water introduced into the reaction).

[0146] In one embodiment of the present disclosure, the total amount of acid (C) is added at the beginning of the reaction. In another embodiment, the acid is added dropwise over a certain period of time during the reaction, provided that the acid (C) is always present during the reaction.

[0147] The present disclosure can also provide the esteramines of the present invention and their salts starting from natural amino acids and / or natural alcohols, thus enabling the provision of products with a high content of bio-derived materials. Since alkylene oxides can also be derived from non-fossil sources, compounds of the present invention containing only carbon atoms from non-fossil sources can be obtained. Such products are being enthusiastically sought after by consumers and industry.

[0148] Treatment composition:

[0149] The treatment composition detailed herein includes at least one fragrance raw material and an esteramine or a salt thereof, which is preferably produced as described above. When compared with esteramines and salts thereof obtained by different reaction methods, the treatment composition using esteramines and salts thereof obtained by the reaction method detailed herein will have less residual fatty alcohol (i.e., alcohol (A) as defined herein). Therefore, due to having less residual fatty alcohol in the treatment composition, the treatment composition will have a better basic odor. This can be confirmed by comparing GC / MS (gas chromatography / mass spectrometry) headspace analysis of the treatment compositions, which differ only in the source of the esteramines and salts thereof used, and the esteramines and salts thereof used will differ due to their derivatization methods.

[0150] The treatment composition can be a consumer product composition. The consumer product composition of the present disclosure can be used for baby care products, beauty care products, fabric care products, home care products, household care products, feminine care products, and / or health care applications. The treatment composition can be used to treat surfaces, such as fabrics, hair or skin. The consumer product composition can be intended to be used or consumed in its sales form. The consumer product composition may not be intended for subsequent commercial manufacturing or modification.

[0151] The treatment composition may be a home care composition.The treatment composition may be a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition (such as a shampoo or conditioner), a body cleansing composition, or mixtures thereof.

[0152] The treatment composition may be a fabric care composition such as a laundry detergent composition (including heavy duty liquid detergents or unit dose products), a fabric conditioning composition (including liquid fabric softening and / or enhancing compositions), a laundry additive, a fabric pretreatment composition (including sprays, pourable liquids or mists), a fabric refresher composition (including sprays) or mixtures thereof.

[0153] The treatment composition may be a cosmetic care composition, such as a hair treatment product (including a shampoo and / or a conditioner), a skin care product (including a cream, lotion or other topically applied product for consumer use), a shave care product (including a shave lotion, foam, or a pre-shave or post-shave treatment), a personal cleansing product (including a liquid body wash, liquid hand soap, and / or a bar soap), a deodorant and / or an antiperspirant, or mixtures thereof.

[0154] The treatment composition may be a home care composition, such as air care, car care, dishwashing, hard surface cleaning and / or treatment, and other cleaning for consumer or institutional use.

[0155] The treatment composition may be in the form of a liquid composition, a granular composition, a hydrocolloid, a single compartment pouch, a multi-compartment pouch, a dissolvable sheet, a lozenge or bead, a fiber product, a tablet, a stick, a strip, a wafer, a foam / mousse, a nonwoven sheet, or a mixture thereof.

[0156] The treatment composition may be in liquid form. The liquid composition may contain from about 30%, or from about 40%, or from about 50% to about 99%, or to about 95%, or to about 90%, or to about 75%, or to about 70%, or to about 60% water by weight of the composition. The liquid composition may be a liquid laundry detergent, a liquid fabric conditioner, a liquid dishwashing detergent, a shampoo, a hair conditioner, or a mixture thereof.

[0157] The treatment composition may be in solid form. The solid composition may be a powdered or granular composition. Such compositions may be agglomerated or spray dried. Such compositions may include a plurality of particles or microparticles, at least some of which include different compositions. The composition may be a powdered or granular cleaning composition, which may contain a bleaching agent. The composition may be in the form of beads or pastilles, which may be made from a liquid melt into beads or pastilles. The composition may be an extruded product.

[0158] The treatment composition may be in the form of particles, such as a plurality of particles. A single particle may have a mass of about 1 mg to about 1 g. The emulsion may be dispersed in a water-soluble carrier. The water-soluble carrier may be selected from the group consisting of polyethylene glycol, sodium acetate, sodium bicarbonate, sodium chloride, sodium silicate, polypropylene glycol polyoxyalkylene, polyethylene glycol fatty acid esters, polyethylene glycol ethers, sodium sulfate, starch, and mixtures thereof. The water-soluble carrier may be a water-soluble polymer. When in the form of particles, the treatment composition may comprise about 25% by weight to about 99.99% by weight of a water-soluble carrier and about 0.001% by weight to about 50% by weight of an esteramine or its salt. The particle form may be in the form of beads or lozenges.

[0159] The treatment composition can be in the form of a combined dose product such as a tablet, a pouch, a sheet or a fiber product. Such pouches generally include a water-soluble film, such as a polyvinyl alcohol water-soluble film, which at least partially encapsulates the composition. Suitable films are available from MonoSol, LLC (Indiana, USA). The composition can be encapsulated in a single compartment pouch or a multi-compartment pouch. The multi-compartment pouch can have at least two, at least three or at least four compartments. The multi-compartment pouch can include compartments arranged side by side and / or stacked. The composition contained in the pouch or its compartment can be a liquid, a solid (such as a powder), or a combination thereof. The bagged composition can have a relatively small amount of water, for example, less than about 20%, or less than about 15%, or less than about 12%, or less than about 10%, or less than about 8% water by weight of the detergent composition.

[0160] The treatment composition may be in the form of a spray and may be dispensed from a bottle, for example, via a trigger sprayer and / or an aerosol container having a valve.

[0161] The treatment composition may have a -1 and a viscosity of 1 centipoise to 1500 centipoise (1 mPa*s to 1500 mPa*s), 100 centipoise to 1000 centipoise (100 mPa*s to 1000 mPa*s), or 200 centipoise to 500 centipoise (200 mPa*s to 500 mPa*s) at 21°C.

[0162] The treatment composition may comprise from about 0.001% to about 30%, preferably from about 0.001% to about 20%, more preferably from about 0.001% to about 15%, 0.001% to about 10%, more preferably from about 0.01% to about 5%, more preferably from about 0.1% to about 3%, more preferably from about 0.5% to about 2% of an esteramine or salt thereof that has been produced by the process as described herein, based on the weight of the treatment composition.

[0163] The corresponding treatment composition may comprise a ratio of orthoester to esteramine or salt thereof of from about 1:20 to about 1:1, more preferably from about 1:15 to about 1:5, more preferably from about 1:12 to about 1:8, more preferably about 1:10.

[0164] The treatment composition may comprise the orthoester present at a level of from about 0.0001% to about 3%, more preferably from about 0.001% to about 0.5%, more preferably from about 0.01% to about 0.3%, even more preferably from about 0.05% to about 0.2% by weight of the treatment composition.

[0165] The treatment composition may comprise from about 0.001% to about 30%, preferably from about 0.001% to about 20%, more preferably from about 0.001% to about 15%, 0.001% to about 10%, more preferably from about 0.01% to about 5%, more preferably from about 0.1% to about 3%, more preferably from about 0.5% to about 2%, by weight of the treatment composition, of at least one perfume raw material.

[0166] At least one perfume raw material may include an aldehyde moiety, a ketone moiety, or a mixture thereof. As used herein, the term "perfume raw material" (or "PRM") refers to a compound that may have a molecular weight of at least about 100 g / mol (optionally up to about 1000 g / mol, preferably up to about 500 g / mol) and may be used alone or with other perfume raw materials to impart an odor, fragrance, flavor, or flavor. Lists of common PRMs can be found in various references, such as "Perfume and Flavor Chemicals", Volumes I and II; Steffen Arctander Allured Pub. Co. (1994) and "Perfumes: Art, Science and Technology", Miller, PM and Lamparsky, D., Blackie Academic and Professional (1994).

[0167] Fragrance raw materials comprising an aldehyde moiety are provided below in Table B. The materials provided in Table B are believed to be illustrative (but non-limiting) examples of PRMs suitable for use in accordance with the present disclosure.

[0168] Table B. Aldehyde-containing fragrance raw materials .

[0169]

[0170]

[0171]

[0172] Perfume raw materials useful in the treatment compositions detailed herein may be selected from the group consisting of the aldehyde-containing PRMs of Table A above. The PRMs useful in the present invention may contain an aldehyde moiety and are preferably selected from the group consisting of: methylnonyl acetaldehyde; benzaldehyde; sea breeze aldehyde; isocyclic citral; (2,4-dimethylcyclohexen-3-yl) formaldehyde (privet aldehyde); methyl citrus aldehyde B; lily aldehyde; decanal; undecenal; cyclamen homoaldehyde; rabbit ear grass aldehyde; dobicar; oncidal; adoc aldehyde; melon aldehyde; 6-methoxy-2,6-dimethyloctanal; anisaldehyde; jasmine aldehyde; cumin aldehyde; qingfeng aldehyde; 3,6-dimethylcyclohexane -3-ene-1-carboxaldehyde; 2-methyl-3-(p-methylphenyl)propanal; consinaldehyde; vanillin; ethyl vanillin; cinnamaldehyde; cis-4-decenal; trans-4-decenal; cis-7-decenal; undecenal; trans-2-hexenal; trans-2-octenal; 2-undecenal; 2,4-dodecenal; cis-4-heptenal; cyanaldehyde; butylcinnamaldehyde; limonelal; amylcinnamaldehyde; hexylcinnamaldehyde; citronellal; citral; cis-3-hexen-1-aldehyde; and mixtures thereof.

[0173] As mentioned above, the perfume raw materials useful in the treatment compositions detailed herein may contain a ketone moiety. Perfume raw materials containing a ketone moiety are provided in Table C below. It is believed that the materials provided in Table C are illustrative (but non-limiting) examples of PRMs suitable for use in accordance with the present disclosure.

[0174] Table C. Ketone-containing flavor raw materials .

[0175]

[0176]

[0177]

[0178] The perfume raw materials useful in the treatment compositions detailed herein may be selected from the group consisting of the ketone-containing PRMs of Table C above. The PRMs useful in the present invention may contain a ketone moiety and may preferably be selected from the group consisting of: nerone; 4-(4-methoxyphenyl)butan-2-one; 1-naphthalen-2-ylethanone; spathone; trimofix O; jasmone; Δ-damascone; β-damascone; α-damascone; methylionone; 2-hexylcyclopent-2-en-1-one; gerpone; and mixtures thereof.

[0179] The treatment compositions detailed herein may utilize a fragrance raw material selected from the group consisting of: methylnonyl acetaldehyde; benzaldehyde; sea breeze aldehyde; isocyclic citral; (2,4-dimethylcyclohexen-3-yl) formaldehyde (privet aldehyde); methyl citrus aldehyde B; lily of the valley aldehyde; decanal; undecenal; cyclamen homoaldehyde; rabbit ear grass aldehyde; dobicar; oncidal; adoc aldehyde; melon aldehyde; 6-methoxy-2,6-dimethyloctanal; anisaldehyde; jasmine aldehyde; cumin aldehyde; 3,6-dimethylcyclohex-3-ene-1-carboxaldehyde; 2-methyl-3-(p- methylphenyl)propanal; conosin aldehyde; vanillin; ethyl vanillin; cinnamaldehyde; cis-4-decenal; trans-4-decenal; cis-7-decenal; undecenal; trans-2-hexenal; trans-2-octenal; 2-undecenal; 2,4-dodecenal; cis-4-heptenal; cyanaldehyde; butylcinnamaldehyde; limonelal; amylcinnamaldehyde; hexylcinnamaldehyde; citronellal; citral; cis-3-hexen-1-al; nerolone; 4-(4-methoxyphenyl)butan-2-one; 1-naphth-2-ylethanone; styraconone; trimofix O; jasmone; Δ-damascone; β-damascone; α-damascone; methylionone; 2-hexylcyclopent-2-en-1-one; gerpentone; and mixtures thereof.

[0180] In the treatment compositions detailed herein, for the perfume raw materials used, it may be preferred that the hydrophobic moiety is an organic group containing from about 8 to about 18 chain atoms, more preferably from about 10 to about 18 chain atoms, preferably wherein the chain atoms are carbon atoms. It is believed that such chain lengths provide a suitable degree of hydrophobicity to promote deposition benefits, particularly in laundry applications where the treatment compositions described herein are aqueous liquids.

[0181] The fragrance raw materials used in this specification, including those listed above, can be purchased from a variety of suppliers, including: International Flavors and Fragrances, New York, NY USA; Givaudan, Vernier Switzerland; Firmenich, Geneva, Switzerland; Symrise, Holzminden, Germany; Kao, Tokyo, Japan; Takasago, Tokyo, Japan; and Florasynth, Tel-Aviv, Israel.

[0182] Auxiliary ingredients

[0183] The treatment composition of the present disclosure, which may be a consumer product, may contain adjuvant materials. The adjuvant material may provide a beneficial effect in the intended end use of the composition, or it may be a processing aid and / or a stabilizing aid.

[0184] Suitable adjunct materials may include: surfactants, conditioning actives, deposition aids, rheology modifiers or structurants, antioxidants, bleach systems, stabilizers, builders, chelants, dye transfer inhibitors, dispersants, enzymes, enzyme stabilizers, catalytic metal complexes, polymeric dispersants, clay and soil removal / anti-redeposition agents, brighteners, suds suppressors, silicones, hueing agents, aesthetic dyes, pure perfumes, perfume delivery systems (such as core / shell encapsulates, other pro-fragrance materials, etc.), structural elasticizers, carriers, hydrotropes, processing aids, anti-agglomeration agents, coatings, formaldehyde scavengers and / or pigments.

[0185] Depending on the intended form, formulation and / or end use, the compositions of the present disclosure may or may not contain one or more of the following adjunct materials: surfactants, conditioning actives, deposition aids, rheology modifiers or structurants, antioxidants, bleach activators, surfactants, builders, chelants, dye transfer inhibitors, dispersants, enzymes and enzyme stabilizers, catalytic metal complexes, polymeric dispersants, clay and soil removal / anti-redeposition agents, brighteners, suds suppressors, dyes, additional perfumes and perfume delivery systems, structural elasticizers, fabric softeners, carriers, hydrotropes, processing aids, structurants, anti-agglomeration agents, coatings, formaldehyde scavengers and / or pigments.

[0186] The specific nature of these additional components and the amount of incorporation thereof will depend on the physical form of the composition and the nature of the operation in which it is used. However, when one or more adjuvants are present, such one or more adjuvants may be present as described in detail below. The following is a non-limiting list of suitable additional adjuvants.

[0187] A. Surfactants

[0188] The treatment composition of the present disclosure may include a surfactant. For example, a surfactant may be used to provide a cleaning benefit. The composition may include a surfactant system, which may include one or more surfactants.

[0189] The treatment compositions of the present disclosure may comprise from about 0.1% to about 70%, or from about 2% to about 60%, or from about 5% to about 50% of the surfactant system by weight of the composition. Liquid compositions may comprise from about 5% to about 40% of the surfactant system by weight of the composition. Compact formulations, including compact liquids, gels and / or compositions suitable for use in unit dosage form, may comprise from about 25% to about 70%, or from about 30% to about 50% of the surfactant system by weight of the composition.

[0190] The surfactant system may include anionic surfactants, nonionic surfactants, zwitterionic surfactants, cationic surfactants, amphoteric surfactants, or combinations thereof. The surfactant system may include linear alkylbenzene sulfonates, alkyl ethoxylated sulfates, alkyl sulfates, nonionic surfactants such as ethoxylated alcohols, amine oxides, or mixtures thereof. The surfactant may be derived at least in part from a natural source, such as a natural raw material alcohol.

[0191] Suitable anionic surfactants may include any conventional anionic surfactants. This may include sulfate detersive surfactants (e.g., alkoxylated and / or non-alkoxylated alkyl sulfate materials) and / or sulfonic acid detersive surfactants (e.g., alkylbenzene sulfonates). Anionic surfactants may be linear, branched, or combinations thereof. Preferred surfactants include linear alkylbenzene sulfonates (LAS), alkyl ethoxylated sulfates (AES), alkyl sulfates (AS), or mixtures thereof. Other suitable anionic surfactants include branched modified alkylbenzene sulfonates (MLAS), methyl ester sulfonates (MES), sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), and / or alkyl ethoxylated carboxylates (AEC). Anionic surfactants may exist in acid form, salt form, or mixtures thereof. Anionic surfactants may be partially or completely neutralized, for example, by alkali metals (e.g., sodium) or amines (e.g., monoethanolamine).

[0192] Surfactant system can comprise nonionic surfactant.Suitable nonionic surfactant comprises alkoxylated fatty alcohol, such as ethoxylated fatty alcohol.Other suitable nonionic surfactant comprises alkoxylated alkylphenol, alkylphenol condensate, mid-chain branched alcohol, mid-chain branched alkyl alkoxylate, alkyl polysaccharide (for example alkyl polyglycoside), polyhydroxy fatty acid amide, ether-terminated poly (alkoxylated) alcohol surfactant and their mixture.Alkoxylate unit can be ethyleneoxy unit, propyleneoxy unit or their mixture.Nonionic surfactant can be linear, branched (for example, mid-chain branched) or their combination.Specific nonionic surfactant can comprise alcohol with average about 12 to about 16 carbon atoms and average about 3 to about 9 ethoxy groups, such as C12-C14 EO7 nonionic surfactant.

[0193] Suitable zwitterionic surfactants may include any conventional zwitterionic surfactants such as betaines, including alkyl dimethyl betaine and cocodimethylamidopropyl betaine, C 8 To C 18 (For example, C 12 To C 18 ) amine oxides (e.g., C 12-14dimethylamine oxide), and / or sulfobetaines and hydroxybetaines, such as N-alkyl-N,N-dimethylamino-1-propanesulfonates, where the alkyl group can be C 8 To C 18 or C 10 To C 14 The zwitterionic surfactant may include an amine oxide.

[0194] Depending on the formulation and / or intended end use, the composition may be substantially free of certain surfactants. For example, a liquid fabric enhancer composition, such as a fabric softener, may be substantially free of anionic surfactants, since such surfactants may interact adversely with cationic ingredients.

[0195] B. Conditioning Actives

[0196] The treatment compositions of the present disclosure may include a conditioning active. Compositions including a conditioning active may provide softness, anti-wrinkle, anti-static, conditioning, anti-stretch, color, and / or appearance benefits.

[0197] Conditioning actives may be present at a level of from about 1% to about 99% by weight of the composition. The composition may contain from about 1%, or from about 2%, or from about 3% to about 99%, or to about 75%, or to about 50%, or to about 40%, or to about 35%, or to about 30%, or to about 25%, or to about 20%, or to about 15%, or to about 10% conditioning actives by weight of the composition. The composition may contain from about 5% to about 30% conditioning actives by weight of the composition.

[0198] Suitable conditioning actives for use in the compositions of the present disclosure may include quaternary ammonium ester compounds, silicones, non-ester quaternary ammonium compounds, amines, fatty esters, sucrose esters, silicones, dispersible polyolefins, polysaccharides, fatty acids, softening or conditioning oils, polymer latexes, polyhydroxystearic acid and / or derivatives thereof, glyceride copolymers, or combinations thereof. Preferably, the conditioning active is a cationic conditioning active, which may improve the delivery / deposition of the benefit agent compound.

[0199] The treatment composition may comprise a conditioning active, wherein the conditioning active comprises a quaternary ammonium ester compound. Preferably, the quaternary ammonium ester compound is present at a level of from about 2% to about 35% by weight, preferably from about 4% to about 25% by weight, more preferably from about 5% to about 20% by weight, even more preferably from about 6% to about 15% by weight, even more preferably from about 7% to about 12% by weight, based on the weight of the treatment composition. The quaternary ammonium ester compound (also referred to as an "ester quat") may be a monoester quat, a diester quat, a triester quat, or a combination thereof; preferably, the diester quat material forms a major portion (whether a majority or a plurality) of the ester quat. It is believed that, in addition to providing conditioning benefits, selecting the appropriate type and / or level of conditioning active (i.e., quaternary ammonium ester compound) may improve the deposition and / or performance of the benefit agent compounds described in the present disclosure.

[0200] The quaternary ammonium ester compound may comprise a compound according to the formula:

[0201] {R 2 (4-m) -N+-[XYR 1 ] m} -

[0202] in:

[0203] m is 1, 2, or 3, provided that in a given molecule, the value of each m is the same;

[0204] Each R may contain from 13 to 22 carbon atoms. 1 are independently a straight chain hydrocarbon group or a branched hydrocarbon group, preferably R 1 is a straight chain, more preferably R 1 is a partially unsaturated straight alkyl chain;

[0205] Each R 2 Independently for C 1 -C 3 alkyl or hydroxyalkyl group, and / or each R 2 Selected from methyl, ethyl, propyl, hydroxyethyl, 2-hydroxypropyl, 1-methyl-2-hydroxyethyl, poly (C 2 -C 3 -alkoxy), polyethoxy, benzyl, more preferably methyl or hydroxyethyl;

[0206] Each X is independently -(CH 2 )n-、-CH 2 -CH(CH 3 )- or -CH(CH 3 )-CH 2-, wherein each n is independently 1, 2, 3 or 4, preferably each n is 2;

[0207] each Y is independently -O-(O)C- or -C(O)-O-; and

[0208] A- is independently selected from the group consisting of chloride, bromide, methylsulfate, ethylsulfate, sulfate and nitrate, preferably A- is selected from the group consisting of chloride and methylsulfate, more preferably A- is methylsulfate.

[0209] For monoester quats, m is 1. For diester quats, m is 2. For triester quats, m is 3. The conditioning active may include a mixture of monoester quats and diester quats, or even a mixture of monoester quats, diester quats, and triester quats. As will be appreciated by those of ordinary skill, the mixture may depend in part on the starting / raw material, such as a dialkanolamine or a trialkanolamine.

[0210] The quaternary ammonium ester compound may be derived from a fatty acid characterized by an iodine value of 0 to 140, or 0 to about 90, or about 10 to about 70, or about 15 to about 50, or about 18 to about 30. The iodine value may be determined according to the method provided in US2020 / 0407665 (equivalent to WO2020 / 264566).

[0211] The composition may include a quaternary ammonium ester compound, a silicone, or a combination thereof, preferably a combination. The total amount of the quaternary ammonium ester compound and the silicone combined may be from about 5% to about 70%, or from about 6% to about 50%, or from about 7% to about 40%, or from about 10% to about 30%, or from about 15% to about 25% by weight of the composition. The composition may include a quaternary ammonium ester compound and silicone in a weight ratio of from about 1:10 to about 10:1, or from about 1:5 to about 5:1, or from about 1:3 to about 1:3, or from about 1:2 to about 2:1, or from about 1:1.5 to about 1.5:1, or about 1:1.

[0212] The composition may contain a mixture of different types of conditioning actives. The composition of the present disclosure may contain certain conditioning actives, but may be substantially free of other conditioning actives. For example, the composition may be free of quaternary ammonium ester compounds, silicones, or both. The composition may contain quaternary ammonium ester compounds, but may be substantially free of silicones. The composition may contain silicones, but may be substantially free of quaternary ammonium ester compounds.

[0213] Conditioning actives may include glyceride copolymers. Glyceride copolymers may be derived from natural oils. Examples of natural oils include, but are not limited to, vegetable oils, algae oils, fish oils, animal fats, tall oils, derivatives of these oils, combinations of any of these oils, etc. Representative non-limiting examples of vegetable oils include rapeseed oil (canola oil), high-erucic rapeseed oil, coconut oil, corn oil, cottonseed oil, olive oil, palm oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, linseed oil, palm kernel oil, tung oil, jatropha oil, mustard seed oil, blue vegetable oil, camellia oil, hempseed oil and castor oil, preferably canola oil. Representative non-limiting examples of animal fats include lard, tallow, poultry fat, butter grease and fish oil. Tall oil is a byproduct of wood pulp manufacturing. Glyceride copolymers may be metathesized unsaturated polyol esters.

[0214] C. Deposition Aid

[0215] The treatment composition of the present disclosure may include a deposition aid. The deposition aid may facilitate the deposition of various benefit agents, including the esteramines or salts thereof of the present disclosure, conditioning actives, perfumes or perfume delivery systems (such as encapsulated perfumes), or combinations thereof, thereby improving the performance benefits of the composition and / or allowing for more efficient formulation of such benefit agents. The composition may include from 0.0001% to 3%, preferably from 0.0005% to 2%, more preferably from 0.001% to 1%, or from about 0.01% to about 0.5%, or from about 0.05% to about 0.3% of a deposition aid by weight of the composition. The deposition aid may be a cationic polymer or an amphoteric polymer, preferably a cationic polymer.

[0216] In general, cationic polymers and methods for their manufacture are known in the literature. Suitable cationic polymers may include quaternary ammonium polymers known as "polyquaternium" polymers, as specified by the International Nomenclature for Cosmetic Ingredients, such as Polyquaternium-6 (poly(diallyldimethylammonium chloride)), Polyquaternium-7 (copolymer of acrylamide and diallyldimethylammonium chloride), Polyquaternium-10 (quaternized hydroxyethylcellulose), Polyquaternium-22 (copolymer of acrylic acid and diallyldimethylammonium chloride), and the like.

[0217] The deposition aid may be selected from the group consisting of polyvinylformamide, partially hydroxylated polyvinylformamide, polyvinylamine, polyethyleneimine, ethoxylated polyethyleneimine, polyvinyl alcohol, polyacrylate, and combinations thereof.

[0218] The cationic polymer may comprise a cationic acrylate and / or a cationic methacrylate. Such polymers may be copolymers, for example also comprising a nonionic monomer, such as acrylamide. The cationic polymer may be linear or cross-linked. The deposition aid may comprise a combination of a linear cationic polymer and a cross-linked cationic polymer.

[0219] The deposition aid may be added simultaneously with the delivery particles (simultaneously with, for example, encapsulated benefit agents, such as encapsulated fragrances) or directly / separately to the consumer product composition. The weight average molecular weight of the polymer may be from 500 to 5,000,000 Daltons, or from 1,000 to 2,000,000 Daltons, or from 2,500 to 1,500,000 Daltons, as measured by size exclusion chromatography relative to polyethylene oxide standards using refractive index (RI) detection. The weight average molecular weight of the cationic polymer may be from 5,000 to 37,500 Daltons.

[0220] D. Additional Perfumes and / or Perfume Delivery Systems

[0221] The treatment compositions of the present disclosure may comprise additional fragrances and / or fragrance delivery systems.

[0222] The treatment compositions of the present disclosure may contain other fragrance raw materials, for example in pure or free form, including PRMs that do not contain aldehyde or ketone moieties. For example, other PRMs may be provided to the treatment composition in the form of pure or free oils, even though they will not be linked to an esteramine or salt thereof. Such mixtures may be desirable, for example, to provide a more complete olfactory experience.

[0223] The treatment composition of the present disclosure may also include pure fragrances, preferably pure fragrance raw materials that do not contain aldehyde or ketone moieties. Preferably, the pure fragrances include alcohol-containing fragrance raw materials. Suitable alcohol-containing fragrance raw materials are known to those of ordinary skill in the art and may include geraniol, citronellol, cinnamyl alcohol, eugenol, etc. That is, the pure fragrances may also include free fragrance raw materials containing aldehyde and / or ketone moieties.

[0224] The treatment composition of the present disclosure may additionally or alternatively include a fragrance delivery system. Such fragrance delivery systems may take the form of polymer-assisted delivery systems. Such fragrance delivery systems may take the form of encapsulates, such as core-shell encapsulates, wherein the core comprises a fragrance raw material and is surrounded by a polymer shell. The polymer shell may include a polymer material derived from polyacrylate, polyurea, polyurethane, polysaccharide, polyvinyl alcohol, melamine, their derivatives or their combinations. Additionally or alternatively, suitable fragrance delivery systems may include known fragrance precursors / aromatic precursor materials.

[0225] Other Materials

[0226] The treatment compositions and / or even premix compositions of the present disclosure may contain unreacted reactants and / or degradation products of the benefit agent compounds described herein. For example, the treatment compositions and / or premix compositions of the present disclosure may contain: precursors or derivatives of individual carbon-containing cores, such as parent amino acids (e.g., H 2 -AH, wherein A is substantially as defined above according to formula III, wherein G = oxygen); a hydrophobically modified amino acid (e.g., H 2 -AQ, wherein A is substantially as defined above according to formula III); a free form of a hydrophobe (e.g., HGQ, such as a fatty alcohol, such as dodecanol); a hydrophobe-free esteramine or salt form thereof (e.g., ZAH, wherein A is substantially as defined above according to formula III, wherein G = oxygen); a free benefit agent, such as an aldehyde- or ketone-containing PRM; or a combination thereof.

[0227] Method for preparing treatment composition

[0228] The present disclosure relates to methods of making any of the compositions described herein.A method of making a treatment composition, which may be a consumer product, may include the step of combining at least one fragrance raw material and an esteramine or salt thereof as described herein with an adjunct material as described herein.

[0229] At least one perfume raw material and / or esteramine or salt compound thereof may be combined with such adjuvant materials by methods including mixing and / or spraying.

[0230] The compositions of the present disclosure can be formulated into any suitable form and prepared by any method selected by the formulator. At least one flavor raw material, esteramine or its salt and auxiliary material can be combined in a batch method, in a circulating loop method, and / or by an online mixing method. Suitable equipment for the method disclosed herein may include a continuous stirred tank reactor, a homogenizer, a turbine agitator, a recirculation pump, a paddle mixer, a high shear mixer, a static mixer, a plow shear mixer, a ribbon blender, a vertical shaft granulator and a drum mixer (the two of which can be in an intermittent process configuration and a continuous process configuration (when available)), a spray dryer and an extruder.

[0231] For example, a method for preparing a treatment composition may include the step of combining at least one fragrance raw material and / or esteramine or salt thereof according to the present disclosure with a base composition (preferably a liquid base composition), wherein the base composition comprises adjuvant ingredients. The method may be performed, for example, in a batch process or in an online mixing process, preferably in an online mixing process.

[0232] The method for preparing a treatment composition may include the step of combining at least one fragrance raw material and / or esteramine or salt thereof, a benefit agent and an adjuvant ingredient as described herein. Preferably, the adjuvant ingredient is part of a base composition, and at least one fragrance raw material, esteramine or salt thereof and / or benefit agent is each added to the base composition as a separate input. The separate inputs may be added sequentially (e.g., in series) or substantially simultaneously. Preferably, the base composition is a liquid. The method may be performed, for example, in a batch process or in an online mixing process, preferably in an online mixing process.

[0233] The method for preparing the treatment composition may include the step of adding a premix to the base composition. As described herein, the premix composition may include at least one fragrance raw material, esteramine or its salt and / or a beneficial agent. As described herein, the premix composition may be obtained by combining at least one fragrance raw material and / or esteramine or its salt as described herein with a beneficial agent. The premix composition may include at least one fragrance raw material and esteramine or its salt according to the present disclosure, for example due to the reaction of esteramine or its salt with a beneficial agent. The premix may optionally contain water. The method may be carried out, for example, in a batch process or in an online mixing process, preferably in an online mixing process. When preparing a treatment composition that is or will be in solid form (such as a PEG-based lozenge), the premix may be particularly preferred. In such cases, it may be useful to remove or reduce water from the premix, for example via a water scavenger such as magnesium sulfate, or by removing it using a molecular sieve or vacuum distillation.

[0234] Methods of surface treatment

[0235] The present disclosure also relates to methods of treating a surface (e.g., a surface of an article) with a treatment composition according to the present disclosure. Such methods can provide cleaning, conditioning, hygiene, and / or freshness benefits.

[0236] Suitable surfaces may include fabrics (including clothing, towels, or linens), hard surfaces (such as tile, porcelain, linoleum, or wood floors), dishes, hair, skin, or mixtures thereof.

[0237] The method may include the step of contacting the article or surface with a treatment composition of the present disclosure, optionally in the presence of water, and optionally also including the step of rinsing and / or drying the article or surface. The treatment composition may be in neat form or diluted in a liquid, such as a wash liquid or a rinse liquid. The treatment composition may be diluted in water before, during or after contacting the surface or article. The surface or article comprising such a surface may be optionally washed and / or rinsed before and / or after the contacting step.

[0238] The method of treating and / or cleaning a surface may comprise the following steps:

[0239] a) optionally washing, rinsing and / or drying the surface;

[0240] b) contacting the surface with a treatment composition as described herein, optionally in the presence of water;

[0241] c) optionally washing and / or rinsing the surface; and

[0242] d) drying the surface, optionally by passive drying and / or via active methods such as a laundry washer dryer.

[0243] For purposes of this disclosure, washing includes, but is not limited to, scrubbing and mechanical agitation. Fabrics may include most any fabric capable of being washed or handled under normal consumer or industrial use conditions.

[0244] Liquids that may contain the disclosed compositions may have a pH of about 3 to about 11.5. Such compositions are typically used at a concentration of about 500 ppm to about 15,000 ppm in solution when diluted. When the wash solvent is water, the water temperature is typically in the range of about 5°C to about 90°C, and when the surface is part of a fabric, the weight ratio of water to fabric is typically from about 1:1 to about 30:1.

[0245] The present disclosure also discloses a method for treating a surface or article, preferably a fabric, with an aqueous treatment liquid, the aqueous treatment liquid comprising an orthoester according to the present disclosure, at least one perfume raw material and an esteramine or a salt thereof. The method may include the step of contacting the surface or article, preferably the fabric, with an aqueous liquid. The esteramine or a salt thereof may be present in the aqueous liquid at a level of about 0.001 ppm (e.g., 1 ppb) to about 1000 ppm by weight.

[0246] The present disclosure also discloses a method for treating a surface or article, preferably a fabric, with an aqueous treatment liquid, the aqueous treatment liquid comprising an orthoester according to the present disclosure, at least one perfume raw material and / or an esteramine or a salt thereof. The method may include the step of contacting the surface or article, preferably the fabric, with an aqueous liquid. The esteramine or a salt thereof may be present in the aqueous liquid at a level of about 001 ppm (e.g., 1 ppb) to about 1000 ppm by weight.

[0247] use

[0248] The present disclosure relates to the use of the presently described treatment compositions for providing a freshness benefit.

[0249] The present disclosure relates to the use of the presently described treatment compositions for providing deodorizing benefits.

[0250] combination

[0251] Specific contemplated combinations of the present disclosure are described herein in the paragraphs with the following subscripts. These combinations are exemplary in nature and not limiting.

[0252] A. A treatment composition comprising at least one perfume raw material and an esteramine of formula (I) or a salt thereof,

[0253]

[0254] where independently of each other:

[0255] t is an integer from 1 to 100;

[0256] For each repeating unit t, A 1 are independently selected from the list consisting of vinyloxy, 1,2-propenyloxy, 1,2-butenyloxy, 2,3-butenyloxy, isobutenyloxy, pentenyloxy, hexenyloxy, styryloxy, decenyloxy, dodecenyloxy, tetradecenyloxy, and hexadecyloxy, wherein for t equal to 1, A 1 The oxygen atom of the group is combined with the B group, and the next A 1 The group is always connected to the previous A 1 Group bonding;

[0257] B 1 are independently selected from the group consisting of: a bond, a straight chain C 1 To C 12 Alkanediyl and branched C 1 To C 12 Alkanediyl;

[0258] R 4 , R 8 and R 12 is selected from the group consisting of: H, linear alkyl, branched alkyl, and cycloalkyl;

[0259] The prerequisite is Z 1 is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and a compound according to formula (II), wherein the compound according to formula (II) is linked to the compound according to formula (I) via a bond marked with *, with the proviso that at least one group R 4 , R 8 and / or R 12 Containing at least 7 or more carbon atoms;

[0260]

[0261] Which independently

[0262] w is an integer from 0 to 12;

[0263] R 13 and R 14 For each repeating unit w is independently selected from the group consisting of: H, linear alkyl, branched alkyl and cycloalkyl;

[0264] R 15 , R 16 , R 17 and R 18 Selected from the group consisting of H, linear alkyl, branched alkyl and cycloalkyl.

[0265] B. The treatment composition of paragraph A, comprising the salt of the esteramine, wherein the salt is formed by at least partial protonation of the amine group by an acid, which is a protic organic acid or an inorganic acid.

[0266] C. The treatment composition of any of paragraphs A to B, wherein the salt is formed by at least partial protonation of the amine group by an acid selected from the group consisting of:

[0267] Methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, citric acid and lactic acid.

[0268] D. A treatment composition according to any one of paragraphs A to C, wherein A 1 For each repeating unit t is independently selected from the list consisting of ethyleneoxy, 1,2-propyleneoxy and 1,2-butenyloxy.

[0269] E. A treatment composition according to any one of paragraphs A to D, wherein Z 1 is selected from the group consisting of alanine, glycine, lysine and a compound according to formula (II), wherein w is an integer ranging from 1 to 4, and wherein said compound according to formula (II) is linked to said compound according to formula (I) via a bond marked with *, with the proviso that at least one group R 4 , R 8 and / or R 12 Contains at least 7 or more carbon atoms.

[0270] F. A treatment composition comprising at least one fragrance raw material and an esteramine or a salt thereof, wherein the esteramine or a salt thereof is obtained by a process using a catalytic amount of at least one orthoester, the process comprising the following steps: a) reaction of: i) at least one amino acid selected from α-amino acids, β-amino acids, γ-amino acids, δ-amino acids, ε-amino acids, etc., such as alanine, glycine, leucine, isoleucine, valine, proline, phenylalanine, arginine, asparagine, aspartic acid, aspartate, glutamine, glutamic acid, histidine, lysine, threonine, tryptophan, tyrosine, cysteine, methionine, serine; α-amino acids having secondary or tertiary amino groups, such as sarcosine, N,N-dimethylglycine; other amino acids, such as 6-aminocaproic acid,

[0271] 4-aminobutyric acid, 3-aminopropionic acid, 12-aminododecanoic acid, 11-aminoundecanoic acid;

[0272] Formally derived from α-lactam (three ring atoms), β-lactam (four ring atoms),

[0273] γ-lactams (five ring atoms) and the like; such lactams are preferably

[0274] β-propiolactam, g-butyrolactam, δ-valerolactam, g-valerolactam, e-caprolactam,

[0275] d-decanoic acid, g-decanoic acid, e-decanoic acid; preferably alanine, valine,

[0276] β-alanine, 6-aminocaproic acid; wherein ii) at least one alcohol (A) carrying at least one hydroxyl group, chosen from monohydric alcohols, dihydric alcohols and polyhydric alcohols, all of which can optionally be alkoxylated, wherein said alkoxylation of said at least one hydroxyl group takes place in a step prior to step a), wherein said alcohol is alkoxylated with at least one alkylene oxide, preferably at least 1 mol up to 200 mol, preferably 1 mol to 100 mol, more preferably up to 50 mol of alkylene oxide per hydroxyl group; in the presence of at least one of: iii) at least one acid (C), chosen from inorganic acids and organic acids, wherein said organic The acid or inorganic acid preferably has a pKa value of -3 to up to +5, more preferably -2.5 to 1.5, preferably at least one organic acid, such as a sulfonic acid, more preferably an alkylsulfonic acid and / or an arylsulfonic acid; and iv) in the presence of at least one orthoester, such as triethyl orthoformate, trimethyl orthoformate, triethyl orthoacetate, trimethyl orthoacetate, etc.; and the orthoester is used in a substoichiometric amount, preferably a catalytic amount (referring to an amino acid); and the alcohol used for esterification is different from the residual alcohol in the orthoester; to produce an esteramine salt; b) optionally neutralizing the obtained esteramine salt with at least one base to obtain the free esteramine.

[0277] G. A treatment composition according to paragraph F, wherein the alcohol (A) is selected from: a. a monohydric alcohol, such as a C1 to C36 alkanol, selected from the following group: a. a non-alkoxylated straight chain C2 to

[0278] C36 alcohols such as mixtures of such alcohols selected from C6 to C22 fatty alcohols, preferably C8 to C22 fatty alcohols, more preferably C12 and C14 fatty alcohols, most preferably C16 and C18 fatty alcohols; non-alkoxylated branched C3 to C36 alcohols such as 2-ethylhexanol,

[0279] 2-propylheptanol, isotridecanol, isononanol, C9-C17 oxo alcohol; alkoxylated linear C2 to C36 alcohols, such as alkoxylated mixtures of C6 to C22 fatty alcohols, preferably alkoxylated mixtures of C8 to C22 fatty alcohols, more preferably alkoxylated mixtures of C12 and C14 fatty alcohols, most preferably alkoxylated mixtures of C16 and C18 fatty alcohols; alkoxylated branched C3 to C36 alcohols, such as alkoxylated 2-ethylhexanol, alkoxylated 2-propylheptanol, alkoxylated isotridecanol, alkoxylated isononanol, alkoxylated C9-C17 oxo alcohols; b. dibasic alcohols, such as alkyl glycols, polyalkoxylated C2-C6-alkanediols carrying at least two hydroxyl groups, c. oligomeric alcohols, such as polyalkoxylated C3-C6-alkanetriols carrying at least three hydroxyl groups, d. polyols, such as sugar alcohols, polyalkoxylated C5-C6 alkanepolyols, glycerols such as diglycerol, triglycerol polyglycerol, dipentaerythritol, tripentaerythritol; and / or e. phenoxyalkanols, such as phenoxyethanol; wherein the alcohol is preferably selected from the following group: monohydric alcohols and alkoxylated diols, oligomeric alcohols and alkoxylated polyols, and the alcohol is even more preferably selected from the following group: monohydric alcohols and alkoxylated diols.

[0280] H. A treatment composition according to any of paragraphs F to G, wherein the alcohol (A) used is an alkoxylated alcohol obtained by alkoxylating at least one hydroxyl group of the alcohol according to claim 2 with one or more alkylene oxides to produce an alkyleneoxy chain comprising one or more moieties derived from an alkylene oxide selected from C2-C22-alkylene oxide, preferably C2-C4-alkylene oxide, while the moieties derived from alkylene oxide can be arranged in random, block or multiblock order or a combination thereof, preferably as blocks, more preferably comprising only one block consisting of ethylene oxide or blocks consisting of two blocks, wherein the first block - preferably the "inner block" directly connected to the hydroxyl group of the alcohol - consists of ethylene oxide, and the second block - preferably the "outer block connected to the ethylene oxide block" - consists of propylene oxide, such diblock even more preferably consisting of 3 to 10 EO-derived moieties and the PO block consisting of 1 to 10 PO-derived moieties.

[0281] I. A treatment composition according to any of paragraphs F to H, wherein the acid (C) is selected from: i) alkylsulfonic acids such as methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, camphorsulfonic acid; alkylarylsulfonic acids, and specifically alkylbenzenesulfonic acids, such as toluenesulfonic acid (including mixtures of isomers thereof), p-toluenesulfonic acid, o-toluenesulfonic acid, m-toluenesulfonic acid, xylenesulfonic acid (mixtures of isomers), 2,6-dimethylbenzenesulfonic acid, 2,5-dimethylbenzenesulfonic acid, 2,4-dimethylbenzenesulfonic acid, 4-dodecylbenzenesulfonic acid, isopropylbenzenesulfonic acid, ethylbenzenesulfonic acid and naphthalenesulfonic acid, preferably p-toluenesulfonic acid and methanesulfonic acid, more preferably methanesulfonic acid.

[0282] ii) inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid;

[0283] Preferably selected from group i).

[0284] J. A treatment composition according to any one of paragraphs F to I, wherein the acid is selected

[0285] (C) allowing the esteramine to be obtained as a salt in the form of a cation, preferably the acid selected is methanesulfonic acid, and the esteramine obtained is a salt in the form of a cation.

[0286] K. A treatment composition according to any one of paragraphs F to J, wherein the amino acid is

[0287] The molar ratio of the hydroxyl groups of the (optionally alkoxylated) alcohol is (0.8*n): 1 to

[0288] (1*n): 1.5, wherein the number of hydroxyl groups of the (optionally alkoxylated) alcohol is n.

[0289] L. The treatment composition of any of paragraphs F to K, wherein the method is performed in a molar ratio of the acid (C) to the amino acid in the range of 0.8:1 to 1:1.2.

[0290] M. A treatment composition according to any of paragraphs F to L, wherein the reaction is carried out under the following conditions in the method: a. at a temperature of 50°C to 200°C, preferably 70°C to 180°C, more preferably 80°C to 160°C, most preferably 120°C to 150°C, such as 60°C, 65°C, 75°C, 85°C, 90°C, 95°C, 100°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, 155°C, 165°C,

[0291] 170°C, 190°C; b. for a period of 1 hour to 30 hours, preferably 2 hours, more preferably 3 hours, even more preferably at least 5 hours, and preferably up to 48

[0292] Hours, more preferably up to 20 hours, even more preferably up to 15 hours, such as preferably 3 hours to 24 hours, more preferably 5 hours to 24 hours, most preferably 10

[0293] hours to 24 hours; and c. at a pressure of 0.001 bar to 10 bar, such as 0.001

[0294] bar, more preferably 0.005 bar, even more preferably 0.1 bar, and preferably up to 8

[0295] bar, more preferably up to 5 bar, even more preferably up to 4 bar, such as 1 bar to 10

[0296] bar, more preferably 1 bar to 5 bar, even more preferably 1 bar to 4 bar, or such as 1 mbar to 1000 mbar, more preferably 100 mbar to 500 mbar.

[0297] N. A treatment composition according to any one of paragraphs F to M, wherein in the method,

[0298] The solvent used for the reaction is selected from water, toluene, xylene, heptanol, cyclohexene, etc.

[0299] Preferably it is water only.

[0300] O. A treatment composition according to any of paragraphs F to N, wherein during or after the reaction, preferably at least during the reaction, water and / or excess alcohol is removed, such removal is preferably performed by applying a gas stream and / or applying a distillation method, such as using a gas, such as an inert gas, such as nitrogen or argon, preferably nitrogen, or steam made from water, preferably using an inert gas, more preferably nitrogen, the distillation method is preferably distillation, more preferably a distillation method under reduced pressure and / or at elevated temperature, preferably both, a more preferred method is using a device such as a Dean-Stark trap, most preferably using a Dean-Stark trap, such removal is more preferably at 0.1

[0301] The vacuum is applied in the range of mbar to 800 mbar, preferably 1 mbar to 500 mbar, and more preferably 10 mbar to 100 mbar and is performed using elevated temperature.

[0302] P. A treatment composition according to any one of paragraphs A to O, wherein the treatment composition is a consumer product, preferably a consumer product selected from a fabric care composition, a hard surface cleaner composition, a dish care composition, a hair care composition, a body cleansing composition or a mixture thereof.

[0303] Q. The treatment composition of any of paragraphs A to P, wherein the treatment composition further comprises a benefit agent.

[0304] R. The treatment composition of any of paragraphs A to Q, wherein the benefit agent is selected from an antimicrobial agent, a pesticide, an insect repellent, an antifungal agent, an herbicide, a hueing dye, an antioxidant, a non-fragrance sensory agent, or a combination thereof.

[0305] S. A treatment composition according to any one of paragraphs A to R, wherein the at least one fragrance raw material is selected from the group consisting of: methylnonyl acetaldehyde: benzaldehyde; sea breeze aldehyde; isocyclic citral; (2,4-dimethylcyclohexen-3-yl) formaldehyde (privet aldehyde); methyl citrus aldehyde B; lily aldehyde; decanal; undecenal; cyclamen homoaldehyde; rabbit ear grass aldehyde; dobicar; oncidal; adoc aldehyde; melon aldehyde; 6-methoxy-2,6-dimethyloctanal; anisaldehyde; jasmine aldehyde; cumin aldehyde; qingfeng aldehyde; 3,6-dimethylcyclohex-3-ene-1-carbaldehyde; 2-methyl-3-(p-methylphenyl) propionaldehyde; consin aldehyde; vanillin;

[0306] Ethyl vanillin; cinnamaldehyde; cis-4-decenal; trans-4-decenal; cis-7-decenal; undecenal; trans-2-hexenal; trans-2-octenal; 2-undecenal; 2,4-dodecenal; cis-4-heptenal; cinnamaldehyde; butylcinnamaldehyde;

[0307] limonelal; amyl cinnamaldehyde; hexyl cinnamaldehyde; citronellal; citral; cis-3-hexen-1-al; nerolone; 4-(4-methoxyphenyl)butan-2-one; 1-naphth-2-ylethanone; styraconone; trimofix O; aramidone; delta-damascone; beta-damascone; alpha-damascone; methylionone; 2-hexylcyclopent-2-en-1-one; gerpentone; and

[0308] mixtures thereof; more preferably wherein the hydrophobic moiety is an organic group comprising from about 8 to about 18 chain atoms, preferably wherein the chain atoms are carbon atoms.

[0309] T. The treatment composition of any of paragraphs A to S, wherein the at least one fragrance raw material comprises an aldehyde moiety.

[0310] U. A treatment composition according to any of paragraphs A to T, wherein the treatment composition further comprises an adjunct ingredient comprising one or more of the following: a surfactant, a conditioning active, a deposition aid, a rheology modifier or structurant, an antioxidant, a bleach system, a stabilizer, a builder, a chelating agent, a dye transfer inhibitor, a dispersant, an enzyme, an enzyme stabilizer, a catalytic metal complex, a polymer dispersant, a clay and soil removal / anti-redeposition agent, a brightener, a suds suppressor, a silicone, a hueing agent, a cosmetic dye, a pure perfume, a perfume delivery system, a structural elasticizer, a carrier, a hydrotrope, a processing aid, an anti-agglomeration agent, a coating, a formaldehyde scavenger and / or a pigment.

[0311] V. A treatment composition according to any of paragraphs A to U, wherein the adjunct ingredient comprises a conditioning active, preferably wherein the conditioning active comprises a quaternary ammonium ester compound, more preferably wherein the quaternary ammonium ester compound is present at a level of from about 2 wt % to about 35 wt %, preferably from about 4 wt % to about 25 wt %, more preferably from about 5 wt % to about 20 wt %, preferably from about 6 wt % to about 15 wt %, more preferably from about 7 wt % to about 12 wt %, based on the weight of the treatment composition.

[0312] W. A treatment composition according to any one of paragraphs A to V, wherein the treatment composition is in the form of a liquid composition, a granular composition, a hydrocolloid, a single compartment pouch, a multi-compartment pouch, a dissolvable sheet, a pastille or bead, a fiber product, a tablet, a stick, a strip, a flake, a foam or mousse, a non-woven sheet, or a mixture thereof, preferably in the form of a liquid composition.

[0313] X. A treatment composition according to any of paragraphs A to W, wherein the esteramine or salt thereof is present in the treatment composition at about 0.001% to about 30%, more preferably about 0.01% to about 5%, more preferably about 0.1% to about 3%, by weight of the treatment composition,

[0314] Even more preferably, it is present at a level of about 0.5% to about 2%.

[0315] Y. A treatment composition according to any one of paragraphs A to X, wherein the at least one fragrance raw material is present in the treatment composition in an amount of about 1% by weight of the treatment composition.

[0316] 0.001% to about 30%, more preferably about 0.01% to about 5%, more preferably about 0.1%

[0317] It is present at a level of about 3%, even more preferably about 0.5% to about 2%.

[0318] Z. A method of treating an article or surface, wherein the method comprises treating the article or surface with a treatment composition according to any of paragraphs A to Y, optionally in the presence of water.

[0319] The dimensions and values ​​disclosed herein are not to be understood as being strictly limited to the exact numerical values ​​cited. Instead, unless otherwise indicated, each such dimension is intended to represent the stated value and a functionally equivalent range around that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm".

[0320] Unless expressly excluded or otherwise limited, each document cited herein, including any cross-referenced or related patent or patent application and any patent application or patent to which this application claims priority or the benefit of, is hereby incorporated by reference in its entirety. The citation of any document is not an admission that it is prior art to any of the present invention disclosed or claimed herein, or an admission that it, by itself or in combination with any one or more of the references, proposes, suggests, or discloses any such invention. In addition, to the extent that any meaning or definition of a term in this invention conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this invention shall govern.

[0321] Although specific embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the art that various other changes and modifications may be made without departing from the spirit and scope of the present invention. Therefore, it is intended that all such changes and modifications within the scope of the present invention be covered in the appended claims.

Claims

1. A treatment composition comprising at least one perfume raw material and an esteramine of formula (I) or a salt thereof, where independently of each other: t is an integer from 1 to 100; for each repeating unit t, A1 is independently selected from the list consisting of vinyloxy, 1,2-propenyloxy, 1,2-butenyloxy, 2,3-butenyloxy, isobutenyloxy, pentenyloxy, hexenyloxy, styryloxy, decenyloxy, dodecenyloxy, tetradecenyloxy and hexadecyloxy, wherein for t equal to 1, the oxygen atom of the A1 group is bonded to the B group and the next A1 group is always bonded to the previous A1 group via an oxygen atom; B1 is independently selected from the group consisting of: a bond, a straight chain C1 to C 12 Alkanediyl and branched C1 to C 12 Alkanediyl; R4, R8 and R 12 is selected from the group consisting of: H, linear alkyl, branched alkyl, and cycloalkyl; Provided that Z1 is selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and a compound according to formula (II), wherein the compound according to formula (II) is linked to the compound according to formula (I) via a bond marked with *, provided that at least one radical R4, R8 and / or R 12 Containing at least 7 or more carbon atoms; Which independently w is an integer from 0 to 12; R 13 and R 14 For each repeating unit w is independently selected from the group consisting of: H, linear alkyl, branched alkyl and cycloalkyl; R 15 , R 16 , R 17 and R 18 Selected from the group consisting of H, linear alkyl, branched alkyl and cycloalkyl.

2. The treatment composition of claim 1, comprising a salt of the esteramine, wherein the salt is formed by at least partial protonation of the amine group by an acid, which is a protic organic acid or an inorganic acid.

3. The treatment composition of claim 1 or 2, wherein the salt is formed by at least partial protonation of an amine group with an acid selected from the group consisting of methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, and lactic acid.

4. The treatment composition according to any preceding claim, wherein A1 is independently for each repeating unit t selected from the list consisting of ethyleneoxy, 1,2-propyleneoxy and 1,2-buteneoxy.

5. A treatment composition according to any preceding claim, wherein Z1 is selected from the group consisting of alanine, glycine, lysine and a compound according to formula (II), wherein w is an integer in the range of 1 to 4, and wherein the compound according to formula (II) is linked to the compound according to formula (I) via a bond marked with *, provided that at least one radical R4, R8 and / or R 12 Contains at least 7 or more carbon atoms.

6. A treatment composition comprising at least one fragrance raw material and an esteramine or a salt thereof, the esteramine or a salt thereof being obtained by a process using a catalytic amount of at least one orthoester, the process comprising the steps of: a) in the presence of iii) and iv), i) and ii) react to produce an esteramine salt: i) at least one amino acid selected from α-amino acids, β-amino acids, γ-amino acids, δ-amino acids, ε-amino acids, etc., such as alanine, glycine, leucine, isoleucine, valine, proline, phenylalanine, arginine, asparagine, aspartic acid, aspartate, glutamine, glutamic acid, histidine, lysine, threonine, tryptophan, tyrosine, cysteine, methionine, serine; α-amino acids having secondary or tertiary amino groups, such as sarcosine, N,N-dimethylglycine; other amino acids, such as 6- aminocaproic acid, 4-aminobutyric acid, 3-aminopropionic acid, 12-aminododecanoic acid, 11-aminoundecanoic acid; amino acids formally derived from the hydrolysis of α-lactams (three ring atoms), β-lactams (four ring atoms), γ-lactams (five ring atoms), etc.; such lactams are preferably β-propiolactam, g-butyrolactam, δ-valerolactam, g-valerolactam, e-caprolactam, d-decanolactam, g-decanolactam, e-decanolactam; preferably alanine, valine, β-alanine, 6-aminocaproic acid; ii) at least one alcohol (A) carrying at least one hydroxyl group, chosen from mono-, di- and polyols, all of which can optionally be alkoxylated, wherein the alkoxylation of the at least one hydroxyl group takes place in a step preceding step a), wherein the alcohol is alkoxylated with at least one alkylene oxide, preferably at least 1 mol up to 200 mol, preferably 1 mol to 100 mol, more preferably up to 50 mol of alkylene oxide per hydroxyl group; iii) at least one acid (C) selected from inorganic acids and organic acids, wherein the organic or inorganic acid preferably has a pKa value of -3 up to +5, more preferably -2.5 to 1.5, preferably at least one organic acid such as a sulfonic acid, more preferably an alkylsulfonic acid and / or an arylsulfonic acid; and iv) in the presence of at least one orthoester, such as triethyl orthoformate, trimethyl orthoformate, triethyl orthoacetate, trimethyl orthoacetate, and the like; The orthoester is used in a substoichiometric amount, preferably a catalytic amount (referring to the amino acid); and The alcohol used for esterification is different from the alcohol remaining in the orthoester; b) optionally neutralizing the obtained esteramine salt with at least one base to obtain the free esteramine; The treatment composition comprises less than 0.5% alcohol (A) by weight of the total composition as a residue of the reaction process used to obtain the esteramine or its salt.

7. The treatment composition according to claim 6, wherein the alcohol (A) is selected from: a. a monohydric alcohol, such as a C1 to C36 alkanol, selected from the following group: a non-alkoxylated linear C2 to C36 alcohol, such as a mixture of such alcohols selected from C6 to C22 fatty alcohols, preferably C8 to C22 fatty alcohols, more preferably C12 and C14 fatty alcohols, most preferably C16 and C18 fatty alcohols; a non-alkoxylated branched C3 to C36 alcohol, such as 2-ethylhexanol, 2-propylheptanol, isotridecanol, isononanol, C9-C17 oxo alcohols; Alkoxylated linear C2 to C36 alcohols, such as alkoxylated mixtures of C6 to C22 fatty alcohols, preferably alkoxylated mixtures of C8 to C22 fatty alcohols, more preferably alkoxylated mixtures of C12 and C14 fatty alcohols, most preferably alkoxylated mixtures of C16 and C18 fatty alcohols; Alkoxylated branched C3 to C36 alcohols, such as alkoxylated 2-ethylhexanol, alkoxylated 2-propylheptanol, alkoxylated isotridecanol, alkoxylated isononanol, alkoxylated C9-C17 oxo alcohols; b. diols, such as alkyl diols, polyalkoxylated C2-C6-alkanediols carrying at least two hydroxyl groups, c. oligomeric alcohols, such as polyalkoxylated C3-C6-alkanetriols carrying at least three hydroxyl groups, d. polyols, such as sugar alcohols, polyalkoxylated C5-C6 alkane polyols, glycerols such as diglycerol, triglycerol polyglycerol, dipentaerythritol, tripentaerythritol; and / or e. phenoxyalkanols, such as phenoxyethanol; Therein the alcohol is preferably selected from the group consisting of monohydric alcohols and alkoxylated diols, oligomeric alcohols and alkoxylated polyols, and the alcohol is even more preferably selected from the group consisting of monohydric alcohols and alkoxylated diols.

8. Treatment composition according to claims 6 to 7, wherein the alcohol (A) used is an alkoxylated alcohol obtained by alkoxylating at least one hydroxyl group of an alcohol according to claim 2 with one or more alkylene oxides to produce an alkyleneoxy chain comprising one or more moieties derived from an alkylene oxide selected from C2-C22-alkylene oxide, preferably C2-C4-alkylene oxide, while the moieties derived from one or more alkylene oxides can be arranged in random, block or multiblock order or a combination thereof, preferably as blocks, more preferably comprising only one block consisting of ethylene oxide or a block consisting of two blocks, wherein a first block - preferably the "inner block" directly connected to the hydroxyl group of the alcohol - consists of ethylene oxide and a second block - preferably the "outer block connected to the ethylene oxide block" - consists of propylene oxide, such diblock even more preferably consisting of 3 to 10 EO-derived moieties and a PO block consisting of 1 to 10 PO-derived moieties.

9. The treatment composition according to claims 6 to 8, wherein the acid (C) is selected from: i) alkylsulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, camphorsulfonic acid; alkylarylsulfonic acids, and in particular alkylbenzenesulfonic acids, such as toluenesulfonic acid (including mixtures of isomers thereof), p-toluenesulfonic acid, o-toluenesulfonic acid, m-toluenesulfonic acid, xylenesulfonic acid (mixtures of isomers), 2,6-dimethylbenzenesulfonic acid, 2,5-dimethylbenzenesulfonic acid, 2,4-dimethylbenzenesulfonic acid, 4-dodecylbenzenesulfonic acid, isopropylbenzenesulfonic acid, ethylbenzenesulfonic acid and naphthalenesulfonic acid, preferably p-toluenesulfonic acid and methanesulfonic acid, more preferably methanesulfonic acid; ii) inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid; Preferably selected from group i).

10. Treatment composition according to claims 6 to 9, wherein the acid (C) is selected such that the esteramine is obtained as a salt in cationic form, preferably the selected acid is methanesulfonic acid and the esteramine obtained is a salt in cationic form.

11. A treatment composition according to claims 6 to 10, wherein the molar ratio of amino acid to hydroxyl groups of the (optionally alkoxylated) alcohol is from (0.8*n):1 to (1*n):1.5, wherein the number of hydroxyl groups of the (optionally alkoxylated) alcohol is n.

12. The treatment composition according to claims 6 to 11, wherein the method is carried out in a molar ratio of the acid (C) to the amino acid in the range of 0.8:1 to 1:1.

2.

13. The treatment composition according to claims 6 to 12, wherein in the method the reaction is carried out under the following conditions: a. at a temperature of 50°C to 200°C, preferably 70°C to 180°C, more preferably 80°C to 160°C, most preferably 120°C to 150°C, such as 60°C, 65°C, 75°C, 85°C, 90°C, 95°C, 100°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, 155°C, 165°C, 170°C, 190°C; b. for a period of 1 hour to 30 hours, preferably 2 hours, more preferably 3 hours, Even more preferably at least 5 hours, and preferably up to 48 hours, more preferably up to 20 hours, even more preferably up to 15 hours, such as preferably 3 hours to 24 hours, more preferably 5 hours to 24 hours, most preferably 10 hours to 24 hours; and c. at a pressure of 0.001 bar to 10 bar, such as 0.001 bar, more preferably 0.005 bar, Even more preferably 0.1 bar, and preferably up to 8 bar, more preferably up to 5 bar, even more preferably up to 4 bar, such as 1 bar to 10 bar, more preferably 1 bar to 5 bar, even more preferably 1 bar to 4 bar, or such as 1 mbar to 1000 mbar, more preferably 100 mbar to 500 mbar.

14. The treatment composition according to claims 6 to 13, wherein in the method, the solvent used for the reaction is selected from water, toluene, xylene, heptanol, cyclohexene, etc., preferably only water.

15. A treatment composition according to claims 6 to 14, wherein during or after the reaction, preferably at least during the reaction, water and / or excess alcohol is removed, such removal is preferably performed by applying a gas flow and / or applying a distillation method, such as using a gas, such as an inert gas, like nitrogen or argon, preferably nitrogen, or steam made from water, preferably using an inert gas, more preferably nitrogen, the distillation method is preferably a distillation, more preferably a distillation method under reduced pressure and / or at elevated temperature, preferably both, more preferred methods use a device such as a Dean-Stark trap, most preferably a Dean-Stark trap, such removal is more preferably performed applying a vacuum in the range of 0.1 mbar to 800 mbar, preferably 1 mbar to 500 mbar, and more preferably 10 mbar to 100 mbar and using elevated temperature.

Images